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Before biomarker discoveries made in research organizations can be commercially utilized in the clinical laboratory settings, many studies 
and surveys need to be completed and many questions answered. Is there 
a market need? Can enough scientific and clinical evidence be generated 
to convince the end users? Is the biomarker patent protectable? Can the 
invention be transferred into a practical product and produced at a scale 
that makes sense financially?
Although commercial product development is not the focus of 
academic research, understanding the requirements of the industry and 
real-life end users are prerequisites for the successful commercialization of 
new biomarker assays. According to marketsandmarkets.com, the global 
biomarkers market is estimated to approach 46 billion euro by 2021. The 
growth is mainly driven by the increasing amount of R&D funding, increa-
sing number of diagnostic applications, increasing number of contract 
research organizations, and high prevalence of cancer.
This handbook collects some of the best practices and pitfalls 
encountered at different phases of biomarker discovery and development, 
as well as patent protection and technology transfer at universities, hospi-
tals and research organizations. The handbook focuses on in vitro diag-
nostics (IVD)-applicable biomarkers, i.e. markers that could potentially be 
examined in clinical specimens to provide information on the health status 
of a person in the healthcare or home settings. Regulatory focus is in the 
European IVD Regulation 2017/746.
The input for the collection has been sought from true-life practices 
which have led to success; practices found in literature and taught by experts 
in the field; opinions, expertise and experience of the different stakeholders 
(incl. end users, companies, TTOs, researchers, financiers), recommenda-
tions found in guidance, regulation or laws, as well as practices learned the 
hard way, i.e. repeatedly failing somewhere in the process and later adap-
ting the process for increased success.
The best practices mainly include practices that are prerequisites for 
successful commercialization, but also practices that have been found to 
promote IVD-applicable biomarker commercialization.
The pitfalls are often the reasons why the commercialization fails 
and are of course something that should be avoided. These can relate for 
example to items or data that is missing or suboptimal, typical obstacles or 
failures somewhere else in the process (e.g. in patenting), or pieces of advice 
received from the industry partners or end users.
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The main target group for the handbook is people involved with 
technology transfer, such as the personnel of Technology Transfer Offices 
(TTOs). However, the presented practices are not intended to be inter-
preted as strict rules but rather a source of inspiration. Optimal ways to 








A biomarker is a characteristic that can be objectively measured and 
evaluated as an indicator of a physiological or pathological process in an 
individual or an individual’s response to a therapeutic intervention. The 
closest synonym to a clinically useful biomarker in the context of IVD is 
an analyte, i.e. a component (molecule) in a clinical specimen the presence, 
absence or concentration of which is measured in an analytical procedure 
such as by a laboratory test to obtain information on an individual’s health 
status. 
The biomarker (or analyte) can e.g. be a nucleic acid, protein, polysac-
charide or metabolite. Alterations found e.g. by clinical inspection, physical 
measurement of organ functions (e.g. blood pressure, cardiogram), or 
microscopy of visual tissue appearance are not included in the scope of the 
current handbook. The scope is also narrowed down to human applica-
tions, although many characteristics and requirements are similar for vete-
rinary applications.
In healthcare, biomarkers have been used to detect, predict and monitor 
disease and to selecting the best therapeutic actions. In the pharmaceutical 
industry, the biomarkers are utilized as versatile tools throughout the drug 
development process. Biomarkers enable evaluating the action of new drug 
candidates on their specific targets, the pharmacological and clinical effi-
cacy of the drug candidates, as well as the anticipated safety risks such as 
drug-induced toxicity. This handbook, however, focuses on IVD-applicable 
biomarkers.
IVD-applicable biomarkers are also increasingly being used for indivi-
dualizing therapies (also known as personalized medicine) so that genetic 
and somatic factors known to influence the patient’s response to treatment 
are taken into account when selecting the best fitting course of treatment. 
Personalized medicine is all about understanding the mechanism of diseases 
and pairing specific drugs with specific diagnostics (also called companion 
diagnostic) based on the disease-specific molecular knowledge.
In all these applications, the clinical benefit and the analytical and diag-
nostic accuracy of the biomarker are crucial to enable efficient translation 
from the discovery to the use in the real-life settings. From a commer-
cialization perspective, successful IP protection, competitiveness with exis-
ting or alternative solutions, as well as fluent interaction and collaboration 
between the academia, industry and end users form the other three corners-
tones of successful biomarker commercialization.
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BEST PRACTICES
•  Establish a clear intended purpose for the test. A new 
biomarker test must provide an answer to an unmet clinical 
need which is correctly understood and confirmed by the real-
life end users. 
•  Establish a dialogue with clinicians early on in the process 
(or other relevant opinion leaders or end users). Establishing 
the clinical need is a natural part of a non-commercial research 
project when the researchers are medical doctors or have other 
competences. Contacts with clinicians allow them to verify the 
clinical relevance of the biomarkers. This dialogue, preferably 
with key opinion leaders, needs to be started as early as possible. 
Literature studies can only partially be employed to establish 
the clinical need. The feedback from the end users (or relevant 
industry in the field, when they are the end users) needs to be 
documented.
•  Learn from the above dialogue. Listen to the opinions and 
potential critique of the potential customers. This will help in 
understanding the limitations of the technology and making 
better practical use of the research, while turning it into some-
thing that benefits the society the most.
2.2 Clinical need
The most important requirement for a new biomarker IVD test is being 
able to answer a clear unmet clinical need. The need must originate from 
(or be confirmed by) the end users and be of type “must have”, not “nice 
to have”, because few paying customers exist for the latter kind. Wider 
acceptance and successful commercialization of a new biomarker test can 
only be gained if it fills a proven and topical need of the end users. (Also see 
the chapter on social, psychological, ethical and legal impacts of testing.)
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PITFALLS
•  Looking for a problem to fit one’s solution (rather than 
answering an existing, significant clinical question or need). 
•  Not listening to the potential customers. The need must origin 
from real-life end users.
•  Bad market analysis: there is a need but also alternative testing 
methods that perform well.
•  The new biomarker threatens an existing business model. The 
novelty creates pressure against any change from those benefi-
ting from the existing model. 
2.3 Clinical utility and clinical benefit
Clinical utility means the ability of an IVD test to positively influence the 
clinical outcome when introduced in the clinical care pathway (synonyms: 
clinical pathway, care pathway, care model, care map, care process). The 
European IVD Regulation (IVDR, 2017/746) also uses the term “clinical 
benefit” in the context of an IVD device having a “positive impact related 
to its function, such as that of screening, monitoring, diagnosis or aid to 
diagnosis of patients, or a positive impact on patient management or public 
health”. Only biomarkers that provide clear clinical benefits will be trans-
lated into clinical use.
BEST PRACTICES
•  A new biomarker test must add benefit for patients and society 
as compared to the existing clinical care pathway. Also, the 
harms related to testing need to be considered. There might also 
be subpopulations in which testing is not justified e.g. due to 
an increased risk of false results or lack of effective treatment. 
•  A new biomarker test must also concretely help clinicians at their 
work. A biomarker test must provide information that reflects 
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the current or future situation of the patient without hindsight. 
The test needs to give a clear answer to a clear clinical question, 
for example by providing a more accurate or timely diagnosis of 
a disease or allowing the clinicians to choose the most efficient 
therapy for the patient belonging to the target population.
•  A new IVD test needs to be directly compatible with the clin-
ical assessment of the patient.
•  There must be a proven link between the biochemical pathway 
of the disease and the biomarker used for its indication. 
•  The expression of the biomarker needs to be specific for the 
indication investigated. Understanding the mechanism of 
disease/therapeutic effect is important.
•  Patent protection of a new biomarker should be started only 
when a clear clinical indication and sufficient scientific evidence 
has been generated.
•  The key criteria for a high-impact IVD-applicable biomarker 
include, e.g. 
  ▫ addresses a significant unmet medical need (or replaces an 
unsatisfying existing solution) with a potentially consider-
able impact on public health
  ▫ allows specific association with the disease in the target 
population or separating patients benefiting from treat-
ment/non-treatment (i.e. aids in medical decision making)
  ▫ provides information that is not readily available by clinical 
assessment
  ▫ determination of the biomarker will result in significant 
improvement in the approval or delivery of care to patients, 
i.e. facilitates therapeutic decisions with low risk of under- 
or over diagnostics
  ▫ is present in sufficiently high levels to be measured by prac-
tical assays
  ▫ is present in the clinical specimen for a sufficiently long 
time window; uses a non-invasive specimen matrix
  ▫ is indicative of the present or future status of the patient
  ▫ has a high potential market size and value as the driving 
force for commercialization




•  Conclusions are drawn too early. Conclusions on the clinical 
utility are drawn based on the first observations (presence or 
concentration is different in the affected and healthy persons at 
group level or between paired specimens). 
•  The use of the new marker requires complex setups. The need 
to use complex, personalized decision models containing 
multiple different markers (or even multiple molecular types of 
markers) in varying combinations can limit the clinical utility of 
new tests. When developing sequential multi-parameter testing 
processes, the correct use must be clear and transparent for the 
clinician.
2.4 Economic evaluations
Understanding the true needs of clinical laboratories is vital. Especially 
because there is increasing pressure to provide cost-effective healthcare, 
which is based on documented guidance and defined “best practices”. 
In a cost-effectiveness analysis (CEA), the objective is to determine how 
to maximize a health benefit (e.g. life expectancy) with a (limited) budget, 
i.e. in a CEA one can compare the relative costs and health outcomes of 
different clinical care pathways. In the closely related “cost minimization 
analysis”, the objective is to find the most inexpensive way of achieving a 
given output (e.g. less hospitalizations due to a specific condition). The 
cost-benefit analysis (CBA) is a more monetary analysis which assesses 
whether the health benefits achieved using a certain testing/therapy 
sequence (clinical care pathway) exceed its costs. The analysis takes into 
account the costs and consequences of testing and typically compare the 
costs and outcomes between new and existing clinical care pathways. 
Health technology assessment (HTA) is an extensive multidisciplinary 
and international assessment of healthcare technologies. It can be used to 
develop internationally consistent practices and guidelines. HTA is needed 
especially when the new test is particularly expensive, particularly important 
for public health, or significant regional variation in use has been observed.
Mini-HTA is a narrower but similarly systematic evaluation that can be 
used by hospitals to assess the conditions and effects of a new method at 
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hospital or local level. Mini-HTA identifies the advantages and disadvan-
tages of the test being assessed, the financial implications and the conse-
quences for the patients and the organization.
The formulation of the question for an economic calculation varies 
depending on the perspective, i.e. whether the analysis is performed by the 
initiative of a test manufacturer, laboratory, hospital, clinician, or payer. 
Payer means an entity (other than the patient) that finances or reimburses 
the cost of health services, such as public healthcare authority, insurance 
company, employer or union. 
BEST PRACTICES
•  New IVD tests are introduced in clinical routine only when 
supported by a strong evidence of improving the patient 
outcome or reducing costs while not compromising the care of 
the patient. 
•  Economic evaluations should be made early by describing how 
the clinical care pathway is made more efficient by using the 
test. For example is the diagnostic accuracy improved so that 
there are fewer unnecessary hospital admissions or fewer addi-
tional tests or diagnostic procedures required.
•  From the perspective of (at least) the payers, cost-efficiency 
often means replacing or decreasing more expensive tests or 
reducing the number of admissions or length-of-stay in hospitals.
•  From the perspective of a clinician, a new test should provide 
more diagnostic sensitivity or specificity or new information 
that adds to the information available from existing tests and 
improve patient outcomes e.g. by allowing selection of the most 
optimal treatment.
•  From the laboratory perspective, it must be possible to incorpo-
rate a new test into the routine workflow and it must be affor-
dable to run, especially since laboratories are under huge pres-
sure to reduce costs. A cumulative number of tests is not ideal 
and a new test should preferably replace an older one (where 
feasible). 
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•  The decision to introduce a new IVD test will be influenced 
by the reimbursement policy, which differs in the several Euro-
pean healthcare systems. On the other hand, positive economic 
evaluation is key for favourable reimbursement decision. Regu-
lators and payers are indicating that marginal improvements are 
less and less likely to be reimbursed in the future, but testing 
strategies may also differ between hospitals depending on the 
diseases they are specialized in.
PITFALLS
•  Prospective cost-analysis and economic evaluations are difficult, 
slow and costly and the true impact and the far-reaching effects 
on clinical outcomes become better understood only with time. 
However, preliminary estimates concerning the economic and 
clinical outcomes are easier to accomplish with the help of an 
expert such as a commercialization consultant who is expe-
rienced in the particular field and has skills in health economics. 
It may yet be difficult to acquire pioneer user sites even for a 
highly promising and cost-effective new marker. Having a new 
marker introduced and reimbursed will take time.
•  Even if no special chemistries or instrumentation is required, 
the cost of a new test may be much higher than the ones 
readily on the market due to the low number of tests used in 
the beginning and the added costs of recent IPR protection, 
product development, performance evaluation and registration 
investments. Health benefits and cost savings achieved by the 
new method are therefore essential. (Also see the chapter on 
competition analysis.)
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2.5 Other impacts of testing
2.5.1 Social, psychological, ethical and legal impacts
Diagnostic testing may have consequences and impacts that reach beyond 
the intended purpose. Other impacts may comprise e.g. ethical, psycholo-
gical, legal and social effects. Although clinical performance studies needs 
to be pre-approved by an ethics committee prior to start, the ethical and 
other considerations often span more broadly than the issues covered in the 
study plans.
BEST PRACTICES
•  Check that the voluntary informed consent of the specimen 
donors (patients or their legal representatives) allows for any 
new (academic or commercial) use planned for the specimens 
or results obtained using them.
•  It must be made clear to the patients what the difference is 
between being a subject in a clinical study and being a patient.
•  Keep in track of the limitations of the biomarker and/or the 
assay format used. When taken to clinical use, the test providers 
need to clearly communicate to clinicians the limitations of use 
for the test and also specify what it cannot be used for.
PITFALLS
•  Information on incurable conditions is needed from the pers-
pective of medical research and drug development. However, 
outside primary diagnostics, providing patients with informa-
tion that cannot be used to treat them may be questionable 
from the perspective of ethics. It is also difficult to justify the 
cost of such testing in the healthcare settings.
•  Testing of hereditary conditions or other severe health risks may 
have psychological impacts for the patient and/or the relatives. 
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Testing just for knowledge’s sake is rarely justified but specific 
measures for intervention or adjusted therapy would need to 
be identified and engaged as a part of the clinical care pathway.
•  When the procedure for definite diagnosis is invasive (such as 
surgical biopsy), it is not only uneconomical but also unethical 
to perform such procedure to a large number of people who 
screen positive only due to the low specificity of the screening 
test. Also, the compliance for an invasive operation may be low 
if the risk of an actual disease is low.
2.5.2 Logistical considerations
2.5.2.1 Centralized testing versus near-patient testing 
The suitability of a biomarker for near-patient testing (also called point-
of-care testing, POCT) depends especially on the urgency of the result 
but also on the turn-around-time (including specimen preparation), ease-
of-use, robustness and diagnostic accuracy of the test, and whether results 
are available rapidly enough by other means. 
It is important to carefully weigh the requirements of near-patient 
testing and the characteristics of a new test intended for such use. Amena-
bility to integration into a laboratory automation system is a typical requi-
rement for a new marker in each case.
BEST PRACTICES
•  Near-patient testing is especially useful in treating patients with 
acute and life-threatening conditions, but also in making rapid 
decisions on the treatment of common infections and chronic 
diseases. If a new biomarker assay facilitates significant advances 
in treating the patients, the requirement for specialized instru-
mentation may be accepted more easily. However, complex, 
multi-step assay procedures will always have limited applicabi-
lity to near-patient testing because of the requirement for either 
skilled (laboratory) personnel or complex instrumentation. 
22
•  During patient transport or in rural settings (e.g. outside cities 
or towns and in developing countries), the choice may be 
between near-patient testing and not testing at all. Near-patient 
testing may also provide benefits including reduced specimen 
volumes e.g. in patients who are tested daily.
•  In rural settings, especially in developing countries, the prere-
quisite for wide use of a test is a low cost. Requirements for 
electricity, cold storage of reagents or professional maintenance 
of instrumentation may not be acceptable in settings where 
diseases are typically diagnosed based on clinical examination 
only and where many individuals remain undertreated anyway.
•  The main advantage of simple manual assay devices such as 
immunochromatographic assays is that instrumentation is not 
necessarily required, but the tests can be performed anywhere 
by anyone. The reader-free tests are typically qualitative or 
semi-quantitative. Disadvantages include operator-dependency 
in interpreting the results. Simple readers and even phone appli-
cations are available for a more quantitative readout. 
•  Instrumentation intended for out-of-laboratory use must need 
minimal maintenance and repair. The calibration and quality 
control (QC) issues need to be planned carefully.
•  Because most of the largest IVD manufacturers and several 
hundred small companies are committed to developing near-pa-
tient testing systems, the spectrum of different assay formats and 
systems is wide. The trend is towards full quantitative, minia-
turized, homogeneous and even non-invasive testing methods 
in the future and there may be a high market potential for such 
technologies.
PITFALLS
•  Increased speed of testing may not always provide a sufficient 
competitive edge for a new test. For the majority of tests, it is 
of minor importance to the patient outcome whether the test 
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2.5.2.2 Self-testing and home healthcare
Self-testing and home healthcare applications are in increase. While diag-
nostic testing in the healthcare settings is mainly performed to detect or 
monitor a disease, the regular consumers are increasingly interested in their 
personal health and for example tests that can be purchased in the internet 
and rule-in or rule-out certain risks of disease even in the absence of symp-
toms. Home healthcare or self-testing can also be relevant for future trends 
in telemedicine, where no direct patient-clinician contact is necessary.
BEST PRACTICES
•  Recreational tests (e.g. genetic tests that are sold directly 
to customers) have an increasing demand. It may not yet be 
sensible to perform diagnostic testing in asymptomatic popula-
tion because false positives are likely to occur frequently.
•  Monitoring of the treatment of already diagnosed (chronic) 
diseases at the home healthcare settings is increasing and has the 
potential of improving clinical outcomes. The home healthcare 
sector is likely to present a huge market for the future.
results are received immediately or after few hours or days. Also, 
it may not be sensible to measure one test on-the-spot and then 
wait for other results from the central lab. Most tests can also be 
performed speedily enough in the central laboratory as STAT 
tests, i.e. by marking the specimens with a “STAT”-sticker and 
placing them in a priority lane in which the tests requested are 
given the highest priority for processing, analysis and reporting. 
(“STAT” is an abbreviation of the Latin word “statim” which 
means immediately, without delay.) 
3 
THE IVD-APPLICABLE  
BIOMARKER PIPELINE
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T he path from candidate discovery to translation into an IVD assay is  long and complicated. FDA has recently launched standardized and 
comprehensive processes for developing biomarkers for use in drug develop-
ment (the Biomarker Qualification Program, BQP). However, in the case 
of IVD-applicable biomarkers, the currently existing regulated processes 
rather target the end products i.e. the IVD devices (assay kits) only. 
For biomarkers that pass the early discovery and the confirmatory proof-
of-principle steps, the immediate next (and much more resource-intensive) 
phase is establishing a specific assay (prototype) for the proof-of-concept 
studies where the analytical and clinical performance characteristics of the 
prototype can be properly assessed. 
3.1 Candidate discovery and biomarker verification studies
The discovery of biomarkers is increasingly performed with semi-quantita-
tive methods that allow the analysis of differential expression of biomarkers 
in the investigated condition. The result of the discovery phase is a list of 
molecules, which are found to be differentially expressed in the case and 
control specimens.
Thousands of candidate biomarkers have been discovered this way and 
the number of publications has exploded in recent years. However, few 
findings enter to the specific assay development phase, pass the evaluation 
of analytical and clinical performance characteristics, and are eventually 
transformed into IVD assays. 
BEST PRACTICES
•  The discovery of a candidate biomarker is just the beginning of 
a long road. To have foreseeable commercial use, the marker (or 
panel of markers) needs to be practical – e.g. can be measured 
with a feasible technical method, in a sufficient time window, 
and with a sufficient throughput – and also improve the clinical 
care pathway in a cost-effective way.
•  It has been estimated that the majority of protein biomarkers 
are linked to multiple diseases and that disease-specific protein 
markers are discovered much more rarely. It is important to 
consider the possibility for a shared molecular pathology across 
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diseases (i.e., lack of specificity) early on when evaluating a new 
candidate.
•  The term “validation” is in regulatory and industry glossaries 
limited to the development of commercial products in a stan-
dardized process of establishing that the performance of a test, 
tool, or instrument is acceptable for its intended purpose. In 
IVDR, product verification and validation documentation is 
meant to comprise the results of all tests and studies undertaken 
to demonstrate the conformity of the IVD device with IVDR 
and the applicable general safety and performance requirements 
(GSPR). The performance evaluation data according to IVDR 
consists of three components: data demonstrating the “scientific 
validity” (association of an analyte with a clinical condition or 
a physiological state), “clinical performance” (ability of a device 
to yield results that are correlated with a particular clinical 
condition or a physiological or pathological process or state in 
accordance with the target population and intended user) and 
“analytical performance” (ability of a device to correctly detect 
or measure a particular analyte) of the test. 
•  To ensure long-lived patent applications with an optimal scope 
and focus, applications should not be filed based on the earliest 
findings because at this stage of discovery most findings are still 
very uncertain and there may not be proof of disease-specifi-
city. Furthermore, an early invention often significantly changes 
along with the more targeted experiments and increased sample 
size: an early patent application may prevent patent protec-
ting the most optimal form of the method or product because 
changes in the patent application are not allowed after the end of 
the first year. (Also see the chapter Patenting versus publishing: 
alternative protection strategies for early phase inventions.) 
•  If you already filed a patent application, the minimum requi-
rement is to revisit your patent protection when new results are 
obtained.
•  It is also important to generate knowledge on the biology of 
the candidate biomarker: where it is expressed, when, for how 
long, how many different manifestations of the molecule exist, 
how stable is the molecule and what is the extent of variation 
between individuals and different ethnicities. 
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PITFALLS
•  Biomarkers that are linked to multiple diseases via shared mole-
cular pathology will not facilitate disease-specific use at least as 
stand-alone tests. 
•  Biomarkers may also be expressed differentially, although they 
have nothing to do with the disease under investigation. For 
example, cellular stress is known as a major reason for detecting 
differences between patients and controls. Such biomarkers will 
not facilitate disease-specific use.
•  It is important to separate candidate biomarkers and verified 
biomarkers to avoid filing patent applications too early. Typical 
signs of the earliest findings, belonging to Technology Readi-
ness Level 1 (TRL1) include:
•  All proof has been generated with a non-targeted discovery 
method such as proteomics or transcriptomics analysis.
•  Results are presented inclusively by comparing the “sick” and 
“healthy” at group level, or as analysis of paired specimens.
•  P-value is used to estimate the significance of the findings.
•  Specimens are not representative of the population but have 
been heavily selected.
•  In the scientific literature, the term “biomarker validation” is 
sometimes incorrectly used to describe the early confirmatory 
process. Formal validation is, however, a standardized and regu-
lated process where typically thousands of prospectively colle-
cted specimens are analysed in a clinical performance study. 
Providing proof for the association of an analyte with a clinical 
condition is referred in the IVDR as to establishing the “scien-
tific validity of an analyte”. The term “verification” should also 
be relatively safe to use.
3.1.1 Clinical specimens
The means for ensuring a high quality of specimens used in biomarker 
studies should be included in the project plan and be an essential part of 
risk management of the project. Specimen integrity is one of the factors 
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of highest importance when making conclusions from the clinical perfor-
mance analysis.
Pairing or matching case and control specimens is often performed at 
the discovery stage because the disease prevalence is often low, because 
random selection could result in imbalance of some factors varying between 
individuals and specimens, and because the throughput of the discovery 
analysis methods is typically low. The extent of specimen picking needs to 
be gradually decreased when the research proceeds.
BEST PRACTICES
•  Prepare a specimen management plan spanning e.g. the 
sampling, handling, stability, preservatives, storage, shipping, 
de-identification, chain-of-custody (an action audit trail that 
contains information when the specimens have been used, by 
whom, for what purpose etc.), patient consent, ethical approval, 
restrictions-for-use and disposal issues following the spirit of 
good clinical practice (GCP).
•  Many retrospective specimens are stored frozen or fixed and 
you need to know something about the stability of the candi-
date biomarkers in the storage conditions early on.
•  In the case of pathological specimens, the origin of the tissue 
needs to be taken into account. Control specimens have to show 
the same localization and the same characterization (e.g., age, 
ethnicity, environmental conditions), and the form of preser-
vation of the pathological and healthy specimens needs to be 
performed with the same protocol. The same goes for specimens 
received from a biobank.
•  The probability of making an erroneous conclusion decreases 
with the increased sample size and decreased extent of specimen 
picking. Although strictly selecting specimens with hindsight 
is necessary in the early phase of discovery, conclusions of the 
ability of a biomarker to discriminate between disease and 
non-disease should be made on specimens better representing 
the target population, i.e. individuals that have been or would 
be tested for the presence of disease. At this stage, many of the 
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findings that first showed a good discrimination ability disap-
pear, a natural phenomenon in the biomarker discovery pipeline. 
•  Blinding of specimens during the test process avoids bias, espe-
cially in case of marginally positive subjects and is a required 
element in the later verification studies.
PITFALLS
•  Diagnostic sensitivity, diagnostic specificity, AUC (Area Under 
Curve in ROC, i.e. Receiver Operating Characteristic curve 
analysis), NPV (Negative Predictive Value) and PPV (Positive 
Predictive Value) calculations are not to be made on heavily 
selected specimens due to the strong bias.
3.1.1.1 Patient consent
When designing a new clinical study, the wording in the voluntary informed 
consent that the patients (or their legal representatives) sign should be 
formulated carefully as it dictates the future use of the specimens. 
BEST PRACTICES
•  Follow the format as suggested by the local ethics committee 
(each of which committees act in accordance with the Declara-
tion of Helsinki for ethical principles for medical research invol-
ving human subjects), but also prepare for continuing research 
and utilization of the results obtained.
•  Try to describe the scope and field of research at a level that is 
not too heavily bound on the ongoing project but rather allows 
use of the collected specimens in future projects involving other 
analysis techniques and/or targeting other molecules. The dura-
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tion of storage of the specimens should be long enough to allow 
such continuing research. 
•  Also incorporate that the results obtained by using the speci-
mens may be used for commercial purposes with the aim of 
producing new and more effective diagnostics and drugs for the 
diseases being investigated.
•  Describe the anonymization process in the case that specimens 
are transferred between organizations. In the patient consent, 
include consent for such transfer.
•  Consult your legal department on which requirements of the 
EU General Data Protection Regulation (GDPR) needs to be 
taken into account in your case.
3.1.2 Statistical versus clinical significance
Clinical significance refers to the practical importance of a scientific obser-
vation. It is used as a tool to quantitatively assess whether the magnitude of 
an observed difference is such that it is relevant to patients. In comparison, 
statistical significance refers to the likelihood of a difference being observed 
due to chance (statistical hypothesis testing). It does not give information 
on the scale or direction of the difference. Different measures are used to 
assess the clinical significance and statistical significance.
Note! Below, examples concern the analysis of group-level findings in 
the early discovery phase (proof-of-principle phase). For any next phase 
(proof-of-concept) studies, see the chapter Specific assay development for 
important measures like diagnostic sensitivity, diagnostic specificity, posi-
tive and negative predictive values, cut-off/reference range and AUC.
BEST PRACTISES
•  Use p-value only to ensure the statistical significance of results. 
If p > 0.05, there is no need to assess the clinical significance of 
results.
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•  Case-control studies are useful for hypothesis generation, 
but their value in assessing the clinical significance of a new 
biomarker is very limited. Rather, perform a panel study prefe-
rring a specific assay platform.
•  Effect size (standardized mean difference between groups) is a 
simple way of quantifying the difference between two groups. 
Effect size = ((mean of patients) – (mean of controls))/SD, where 
SD (standard deviation) is the spread of values in the non-affe-
cted (control) group (or both groups in case the control group 
does not represent the healthy population). Effect size allows 
assessing the significance of the result as quantitative difference 
without confusing it with the resolution of the difference (like 
p-value does). It is important to discuss whether a clinician 
would concern the observed absolute value (difference) clini-
cally relevant.
•  The 95 % confidence intervals (CIs) give the likely range of 
the effect size and allow assessing the clinical significance (e.g. 
of concentrations) quantitatively on the case-by-case-level. The 
upper 95 % CI indicates how large the difference can be at its 
highest. 
•  In the case of a new diagnostic biomarker, one is able to esti-
mate if the difference of the biomarker concentration in the 
affected people is large enough to convince the clinicians. One 
can assess all the dots (patients) within the CI similarly – could 
the clinician see a difference large enough to catch his/her eye 
in the routine settings? 
•  When evaluating CIs in relation with statistically calculated 
values such as risk ratios, the width of the CI directly shows 
how precise the estimate is – the narrower the CI, the more 
reliable the estimate.
•  Ratios are useful e.g. in making findings comparable with each 
other, estimating a risk for a certain outcome, or comparing the 
effect of different interventions.
•  Relative risk or risk ratio (RR) compares the probability of an 
event/outcome in the selected group to the probability of the 
event/outcome in the control group. The further away from 1.0, 
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the greater the effect size, i.e. difference in probability. RR > 1 
means the risk of outcome is increased (e.g. exposure causes 
disease) while RR < 1 means the risk is decreased (e.g. exposure 
decreases disease).
•  Odds ratio (OR) is presented as a measure of the effect size 
when RR cannot be calculated (such as in the case of paired case-
control specimens). OR can be used e.g. to assess how strongly 
a certain gene pattern is associated with a given (rare) disease 
in the population. The problem with OR is that it always gives 
a much more impressive value than RR, resulting the reader 
to overestimate the risk of the given event in the population 
assessed. Therefore, always calculate RR where feasible (i.e. 
when prevalence or incidence data is available) or compare ORs 
received with those obtained in closely related studies.
•  Hazard ratio (HR) is RR averaged over the duration of the 
trial, i.e. it measures the effect of an intervention (or a strati-
fication criteria) to an outcome over time. HR is used almost 
solely together with Kaplan-Meier (survival) curves comparing 
the outcome of a group with specific intervention/ stratificati-
on-pattern with a control group. 
•  Always avoid using a complex algorithm when you can use a 
simple ratio.
PITFALLS
•  A small p-value does not necessarily have a practical impact 
and does not guarantee that the difference is clinically useful. 
Large sample sizes just give high resolution – so high that even 
the smallest differences between groups can often be detected. 
Results that are statistically significant can just as well be clini-
cally irrelevant and have no true impact on the treatment of 
patients. Other assessments to judge the clinical significance are 
required.
•  Case-control studies are inherently biased studies. The extent of 
sample picking needs to be decreased in the verification studies.
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3.1.3 Compliance with regulatory requirements
The regulatory requirements related to commercial IVD product develop-
ment set the rules for producing the proof and documentation for product 
registration (such as CE-marking) and meeting with the stringent quality 
requirements for manufacture. Complying with the regulatory require-
ments is the core competence of the companies productizing, manufactu-
ring and selling IVD products. 
The academic organizations rarely have resources for commercial 
product development and manufacture, let alone marketing and distribu-
tion. However, in the research settings it is important not only to adopt 
good scientific practices, but also to understand the prerequisites of IVD 
test development and registration issues, although the key competence in 
the academia would remain in finding and proving the technically and 
clinically optimal approaches.
BEST PRACTICES
•  Proper documentation of all the experimental designs, reagents 
(including manufacturer, product code, lot, expiry date, storage 
conditions), key intermediate products and tools, exact assay 
conditions (e.g. instead of “RT”), replicates/repeats, instrumen-
tation (incl. instrument qualification and calibration informa-
tion and all settings and specifications) etc. early on is crucial for 
later registration and commercialization of a new assay concept. 
Even the early documentation should follow the spirit of Good 
Laboratory Practice (GLP).
PITFALLS
•  If proper documentation of the early phases of research is 
missing, it will become a pain later when the regulatory submis-
sions are topical. For example, all intermediate results and tools 
(such as cloning plasmids) need to be properly documented, 
even though they would not be needed later in the development.
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3.2 Specific assay development
Research laboratories and routine clinical laboratories differ from each 
other to a significant extent. In research settings, more resources (such as 
the researcher him/herself ) are available for managing the high-tech labo-
ratory instrumentation or complex experiments, as well as for troubles-
hooting any technical issues arising. In a busy routine laboratory it is diffi-
cult to allocate staff for performing manual assay steps, operating non- or 
semi-automated instrumentation, or interpreting raw data.
An important early step of the translation process of a scientific finding 
into clinical test is changing the methodology used during the discovery 
phase for a specific, practical and up-scalable testing format. The aim is 
to achieve a simpler, faster, cheaper, automatable and more specifically 
targeted prototype assay.
3.2.1 Establishing a prototype in a specific assay platform
BEST PRACTICES
•  Consider the specific testing platform early. Using an already 
established platform has a higher probability of success. Estab-
lished platforms include e.g. immunoassays, nucleic acid ampli-
fication methods, microarrays, sequencing assays and immuno-
fluorescence, but also other methodologies such as those based 
on mass spectrometry (MS) are becoming widespread (consult 
the intended end users).
•  Converting the assay into a specific and practical prototype 
assay early on is important also because it may turn out difficult 
or even impossible to do. If you have several biomarker candi-
dates to choose from at the proof-of-concept phase, focus on 
candidates that are most amenable to robust and specific assay 
design. It is important to ensure that the analytical sensitivity 
of the method is sufficient for the biomarker of interest, i.e. the 
clinical concentrations of the biomarker fall within the linear 
measuring range.
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•  Ensuring that raw materials needed for the assay are commer-
cially available (or can be made available) at GMP grade from 
an accredited manufacturer is a part of making preparations for 
prototype assays that can be commercialized with reasonable 
efforts (also see the chapter on FTO). 
•  For the same reason, the need for specialized instrumentation 
or modified chemistries should be reasoned with an undisputed 
inapplicability of the more conventional tools and means, not 
getting stuck with the methods used in the discovery phase. 
Unnecessarily binding the new assay (and IPR) to a special 
component or method may also significantly limit the number 
of potential licensees.
PITFALLS
•  Sticking to the use of a technical platform that is available 
almost only for research will delay the introduction of an assay 
to clinical settings.
•  Other characteristics limiting the routine use of a testing plat-
form include low-volume automatization, low throughput 
and batch-wise analysis (results not available on demand; only 
suitable for non-urgent tests).
•  A rare test that requires a fast response has a low chance in 
finding a place in routine.
•  Diagnostic methods that require complex combinations of alter-
native tests (i.e. a long decision-making tree) may be considered 
to involve too much computing, resulting in clinicians losing 
their touch about the decision they should take and therefore 
compromising their individual competences and responsibili-
ties as experts on certain diseases. Any decision-making trees 
should be understandable by one look.
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3.2.2 Analytical performance characteristics
Analytical performance characteristics refer to the ability of a test to conform 
to predefined technical specifications. There are two main types of perfor-
mance characteristics: those for practicability (e.g., required skills, speci-
mens accepted, criteria for specimen collection and handling, turn-around 
time) and those for reliability (e.g., accuracy of measurement (resulting 
from trueness and precision), trueness (i.e., bias), precision of measurement 
(i.e., repeatability and reproducibility), analytical sensitivity (i.e., limit of 
detection), limit of quantification, interference, linearity, measuring range 
and control of known relevant endogenous and exogenous interference and 
cross-reactions). 
It is mainly the clinical use that dictates the requirement specifications 
for the analytical performance characteristics. 
3.2.2.1 Practicability characteristics
The important steps in the translation of scientific findings into routine 
IVD assays include gaining more knowledge of the biomarkers and their 
characteristics, as well as changing any high-tech or non-targeted methodo-
logy used in the discovery phase into a specific, economical and up-scalable 
testing format such as immunoassay, PCR, or other assay format used in 
the clinical settings.
BEST PRACTICES
•  Pre-analytical requirements for a suggested new biomarker 
must be thoroughly studied at an early stage.
•  Use a checklist for e.g. the following practicability parameters:
  ▫ specimen type 
  · availability – is the specimen collected routinely and 
can the commercial sample collecting devices be used?
  · invasiveness – is it in accordance to the type of test/
use of result? Is the (invasive) specimen collected in 
each case? 
  ▫ stability of the biomarker in the selected specimen type; 
appropriate specimen collection, processing and storage 
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3.2.2.2 Reliability characteristics
Along with practicability characteristics, reliability requirements are the 
second type of performance characteristics that are important in the trans-
lation of biomarker discoveries into IVD assays. The reliability characte-
ristics include parameters such as precision of measurement, limit of dete-
ction, limit of quantification (or functional detection limit), interference, 
linearity and measuring range. 
While the reliability of the actual measurements can be significantly 
increased by commercial assay development, the importance of the more 
profound characteristics such as diagnostic accuracy naturally increase 
when the result has a direct effect on a medical decision. Generally, impor-
tant decisions such as proceeding into surgery or biopsy should not be 
based on results with a high diagnostic inaccuracy, originating for example 
from a low number of true positives amongst a high excess of false ones, 
i.e. low prevalence of the biomarker. When the next step is further testing, 
the diagnostic sensitivity needs to be sufficient to catch most of the cases.
protocols. Does the molecule become modified after 
extracting it from the circulation? 
  ▫ expression of the biomarker in relation to the indication 
(timing, duration, concentration range, alternative mani-
festations of the molecule)
  ▫ scalability and amenability to automation
  · required hands-on-time
  · in case of near-patient or home tests, the required 
manual steps
  ▫ total turn-around-time
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BEST PRACTICES
•  Use a checklist for e.g. the following parameters:
  ▫ Analytical limit of detection (typically blank + 3 SD)
  ▫ Limit of quantification/functional detection limit/analy-
tical sensitivity (typically CVconc < 10 -20 %)
  ▫ Linear measuring range vs. clinically relevant concentration 
range (the medical decision level must lie in the linear part 
of the measuring range)
  ▫ Assessment of potential hook-effect with high analyte 
concentrations (immunoassays)
  ▫ Recovery in clinical specimens (spiked specimens)
  ▫ Precision of measurement and repeatability (within-run, 
between-run, between-day etc.)
  ▫ Within- and between-subject variation and whether e.g. 
fasting state, circadian rhythm, age, gender, ethnicity 
affects the results 
  ▫ Analytical specificity and cross-reactivity
  ▫ Matrix effects and interference in clinical specimens (need 
for removing or blocking disturbing molecules)
  ▫ Area-under-curve (AUC) and optimal exemplary cut-off 
value or reference range
  ▫ Diagnostic sensitivity and specificity (diagnostic accuracy) 
using the suggested exemplary cut-off value or reference 
range (from apparently healthy individuals)
  ▫ Prevalence calculations along with positive predictive value 
(PPV) and negative predictive value (NPV)
  ▫ True detected PPV and NPV.
PITFALLS
•  Interference by endogenous biological substances can be a 
complex problem in IVD assays. Both positive and negative 
interference can occur and be very unpredictable in nature. 
False results may also be caused by several other mechanisms, 
including cross-reactivity or low sensitivity for some molecular 
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3.2.3 Clinical performance characteristics
Clinical performance refers to the ability of a test to detect patients with 
specific clinical condition or physiological state. It is about demonstra-
ting that the biomarker is associated with the intended condition in the 
intended target population in an extent that positively affects treating of 
the patients.
BEST PRACTICES
•  The criteria for the clinical performance and the appropriate 
study design need to be decided beforehand based on the 
intended use of the test. Characteristics include e.g. diagnostic 
(i.e. clinical) sensitivity, diagnostic (i.e. clinical) specificity, posi-
tive predictive value (PPV), negative predictive value (s), and 
expected values in normal and affected populations (reference 
range or cut-off).
•  If the test does not achieve the pre-defined clinical performance 
criteria in the performance evaluation study (and it is not a 
question of optimization), further evaluation or patent protec-
tion is not required. Alternative uses of the marker can be consi-
dered (e.g. use in another related indication, such as prognostics 
or monitoring instead of diagnostics).
forms of the analyte. It is not realistic to expect the commercia-
lization partner to solve the problems later in the assay develop-
ment process, but they should be solved earlier.
•  Complex specimen preparation methods are not suitable for 
routine use, but the methods need to be amenable to automa-
tion as far as possible. Labour-intensive steps such as freeze/
thaw cycles need to be avoided. In case of near-patient testing, 
any manual steps sensitive to the knowhow or experience of the 
operator need to be eliminated.
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BEST PRACTICES
•  Positive predictive value (PPV) and negative predictive value 
(NPV) take into account the prevalence of the disease when 
evaluating the clinical performance characteristics of new 
assays. In the above example (diagnostic sensitivity and speci-
ficity 99 %), the positive predictive value would be about 2 %. 
This means that only about 2 % of the persons testing positive 
are actually ill.
3.2.3.1 Effect of prevalence on test performance
Prevalence of the disease targeted has a high impact on the accuracy of 
screening tests and diagnostic tests. A new biomarker test for a rare disease 
would have to be extremely accurate (specific) in order to not produce 
many false positive results amongst the high excess of not-affected people.
For example: The prevalence of a disease is about 20 cases/100 000 indi-
viduals, all of whom belong in the target population of the test. If you use 
an assay with 99 % diagnostic sensitivity and test all the 100 000 indivi-
duals, you will probably catch all the 20 cases with the disease. However, 
if the diagnostic specificity of your assay is 99 %, you will get 1 % of false 
positive results, which is 1 000 cases. This means 50 false positives for each 
true positive case. If your diagnostic specificity is 95 %, you will get 5 % 
false positives, which is 5 000 cases, 250 for each true positive.
PITFALLS
•  Assay optimization is more demanding for tests targeting rare 
or low-prevalence diseases due to the generation of false positive 
results amongst large excess of non-affected people.
•  Furthermore, proper performance evaluation of the test might 
be problematic unless a special source (such as specialized clinic 
or research group) of positive specimens is identified. 
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3.2.3.2 Application-specific requirements
There are many types of IVD test categories.
Diagnostic assays are used to identify the presence or absence of disease in 
symptomatic individuals, and the desirable result is that the test is positive 
only in case of disease. The clinical performance of a diagnostic assay can be 
evaluated in a diagnostic accuracy study, where the test is compared with a 
reference standard and/or another assay in a patient population suspected 
of having the disease.
A prognostic assay is used to infer the risk for a disease-related event. The 
clinical performance of a prognostic marker is demonstrated by estab-
lishing the association between the biomarker and the event of interest. 
While a prognostic marker allows predicting the overall clinical outcome of 
a patient (regardless of therapy), it typically also allow to identify patients 
likely to benefit from more intensive therapy or at least closer monitoring.
Predictive assays help identifying patients most likely to respond to a 
specific intervention.
Staging biomarkers correlate with the stage of the disease in readily diag-
nosed patients.
Monitoring tests employ biomarkers that rapidly respond to a change in 
the clinical course of the disease under investigation.
Risk prediction tests will prospectively identify healthy individuals at an 
increased risk of developing disease.
Screening tests are used to test asymptomatic individuals for latent disease.
Companion diagnostic tests allow determining the applicability of a thera-
peutic drug to a specific person.
Performance requirements are slightly different from class to class, and 
also the strategy of incorporating the new test in the clinical care pathway 
affects the design of the performance evaluation studies.
3.2.3.2.1    Replacing versus add-on/complementary tests
Defining the position of the test in the clinical care pathway is one of the 
determinants when selecting the most appropriate strategy for the perfor-
mance evaluation studies. 
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BEST PRACTICES
•  If the new test is to replace an existing one, it is most prac-
tical and useful to directly compare the diagnostic accuracy of 
the new and old tests against a common standard or clinical 
outcome. 
•  If the new test is to supplement the clinical care pathway by 
bringing new information that will help to treat the patient 
the most optimal way, a comparison is required where the 
new combination of tests is compared with the existing test or 
process.
•  The commercialization of an add-on test is considered more 
straightforward because of the lower extent of competition 
with the existing test providers. Even so, establishing the added 
clinical benefit (without a risk for over-diagnosis) is similarly 
important.
BEST PRACTICES
•  The most important requirement for a screening biomarker 
is to fulfil the main goal of a screening program, which is to 
detect the illness at a stage early enough so that treatment is 
3.2.3.2.2 Screening tests
Biomarkers intended for screening probably face the strictest requirements 
amongst the many classes of test applications. High emphasis is put on 
characteristics like non-invasiveness, low cost, simplicity-to-perform and 
diagnostic accuracy -- in terms of both diagnostic sensitivity and diagnostic 
specificity.
For population screening to be justified, there should be little doubt 
of the net benefit of the program. Reductions in morbidity and mortality 
are to surpass the costs of screening and treatment, as well as the further 
processing of people who falsely screen positive.
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more successful and cheaper than if detected later. In many 
cases, early detection means year(s) before clinical symptoms 
arise. Establishing time-depended ROC curves (corresponding 
to different time lags between testing and the clinical diagnosis) 
can be very informative. Success of treating is mainly measured 
as a decrease in mortality.
•  Another high priority for a screening test is high specificity, 
translating into a low false-positive rate. Each false positive 
subjects a person to unnecessary further testing or diagnostic 
procedure, which, especially when invasive, are expensive and 
burdening for healthcare and increase the trouble and anxiety 
of the patients.
•  False negatives, resulting from low sensitivity, jeopardize the 
entire idea of the screening program and hence a very low false 
negative rate is typically accepted.
•  The acceptable false result rates will vary with the disease, its 
prevalence, the work-up of people screening positive and the 
consequences for people screening false negative. The issues are 
to be addressed and discussed early on.
•  The screening test itself needs to be non-invasive and inexpen-
sive to facilitate its widespread use and compliance of the people 
screened. For example, a blood-based test improves the screening 
compliance and is likely decrease the cost of screening.
•  If the biomarker discriminates well only in a certain subpopula-
tion, it might be valuable for screening that selected population.
PITFALLS
•  Cancers are often a heterogeneous group of cases ranging from 
aggressive and metastatic forms to minimally progressive forms. 
Catching and treating the slow growing forms early, before 
clinical manifestations, is not what is pursued by screening, as 
the clinical outcome of the patient is often the same. For example, 
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3.2.3.2.3 Personalized medicine and companion diagnostics
There is an increasing interest of multiple stakeholders (including diag-
nostic and pharmaceutical companies, registration authorities, payers, 
taxpayers, hospitals, clinicians and patients) in ensuring that the clinical 
trials succeed and that the expensive drugs will give an effective response 
in the treatment of selected patients. There is an important and increasing 
trend in using biomarkers in personalized medicine, aiming in efficiently 
combining diagnostics and best fitting therapeutics. 
However, the implementation of the so-called companion diagnostics 
is still slow-paced and requires exceptionally deep collaboration amongst 
many stakeholders such as the diagnostic and pharmaceutical companies, 
regulatory authorities, payers, healthcare providers and clinicians. In the 
current situation, more pitfalls than best practices has been identified from 
the assay developer’s perspective.
the PSA-based screening programs have been observed to catch 
slowly progressing cancer forms in a significant proportion. 
•  Similarly, a biomarker assay that misses an aggressive subgroup 
of cancers (e.g. a specific mutation) is not optimal for screening. 
•  Diseases that cannot be successfully treated (such as aggres-
sive gliomas) are not optimal for screening, as little benefit can 
derived from information only. Discovery of new biomarkers 
can yet support drug development e.g. by allowing a tool for 
stratifying patients for clinical trials.
•  Diseases that in the absence of a screening program would not 
be detected and would not cause high morbidity and mortality 
are not suitable for screening (such as benign tumours).
•  Early diagnosis due to screening may also lead to a faulty 
conclusion of increased survival time. This is because survival 
is calculated from the time of diagnosis, which is earlier for the 
cases caught by screening than for those with clinical symptoms.
•  A biomarker that only indicates the disease close to the time of 
clinical diagnosis shows low promise for screening and limited 
add-on value (unless existing diagnostic tool are very expensive).
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BEST PRACTICES
•  Introducing companion diagnostics when launching a new 
(expensive) drug is a new trend that comes with benefits like 
cost reductions for the hospitals and avoiding inefficient treat-
ment pathways for some of the patients. When working on such 
an assay, enter in dialog with the drug owner as early as possible, 
and at least before entering the international PCT-phase of 
patent prosecution. This is to allow the company not only to 
express their interest in entering license negotiations and a 
(co-)development project (without which the patent may be 
worthless due to limitations in FTO and/or number of poten-
tial other utilizers), but also the possibility to affect the type and 
scope of the patent protection applied. 
PITFALLS
•  Differentiation between patients at routine clinical settings is 
needless, if you do not have the opportunity to differentiate 
the treatment. Such stratification does not fall within the scope 
of personalized medicine (but can lead to it via drug develop-
ment). 
•  The number of different patient groups and the number of 
individuals in each group can be unbalanced compared to 
the available treatments. Developing companion diagnostics 
requires thorough assessment of the benefit of testing.
•  For a companion diagnostic assay, close partnership (co-de-
velopment) is key in the regulatory approval and commercial 
launch the assay and drug. The market risk for the assay deve-
loper is significantly increased due to the lack of alternative 
commercialization pathways and partnerships, as well as depen-
dence on the success of the therapeutics. 
•  In the research settings, a test suitable for companion diagnos-
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3.3 Diseases with no existing biomarkers
There remains to be a relatively long list of diseases and conditions with no 
existing biomarkers to test at the moment. The Handbook of Biomarkers 
(Jain 2017, 2nd edition, Humana Press, ISBN 978-1-4939-7430-6, doi: 
10.1007/978-1-4939-7431-3) provides a good overview of this issue.
Although the commercial potential for pioneering markers is high in 
the long term, it is likely to take years and even decades to collect enough 
clinical evidence to convince the clinicians. Also, the clinical performance 
evaluation studies and acquiring the regulatory approvals for an IVD test 
that cannot be compared with an existing one are much more complex by 
default. 
PITFALLS
•  If preceding biomarkers are completely missing for a specific 
indication, it often significantly slows down the introduction 
of a pioneering biomarker both from the regulatory perspective 
and from the perspective of acceptance into clinical use. Signi-
ficant clinical evidence is expected to change a current clinical 
care pathway to include the assessment of a biomarker for the 
first time.
tics for a certain drug is often developed only after the drug has 
already entered the market. In that case many of the clinical 
trials have been performed without the accompanying test. A 
widespread introduction of a companion diagnostics test at this 
point requires that the level of added benefit is significant and 
in accordance with the financial aims of the company. If not, 
and if the use would be limited to singular hospitals, the patient 
group may not be large enough to exclude the effect of the drug 
on specific patients. The interest of a drug company needs to be 
confirmed early!
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•  Especially in the case of some acutely life threatening condi-
tions and traumas causing high morbidity and mortality, in 
vitro diagnostics are rarely considered accurate enough to yield 
definite results that could be used to guide the treatment of 
the severely ill patients (such as patients with traumatic brain 
damage). Sometimes, the tests may also be too slow to provide 
support for acute decisions and/or accurately reflect the current 
situation of the patient. Although many imaging and surgery 
methods are invasive for the patient and expensive for the heal-
thcare provider, they often remain the only way to obtain direct 
and definite results.
•  In the absence of sufficiently efficient markers, the use of 
biomarkers for certain indications may even be declined by the 
current care guidelines. Approaches that are now considered 
non-acceptable are likely to be too difficult to commercialize 
within the resources and time span available for universities and 
research organizations. 
•  In any of the above cases, protection and commercialization 
is most feasible for markers showing ground-breaking results 
that simultaneously enable sound IP protection. Even in such 
case, the industry and end users need to be consulted early on. 
It also needs to be kept in mind that the companies expect the 
academia to carry their weight to prove the clinical benefit of a 
new marker. Both the companies and the end users expect to 






The future customers (clinicians, hospitals, laboratories, pharmaceutical 
companies or other intended end users) are the best mirror for a suggested 
new product. 
BEST PRACTICES
•  Discussions with the relevant industry and end users, especially 
including clinicians, should be started early on to get valuable 
input for project planning, steering and management. 
•  Discussions to obtain feedback can be carried out on the 
non-confidential level by encoding or hiding the details of the 
invention. Care needs yet to be taken in all communication 
(also including interviews, presentations and seminars) - espe-
cially prior to submitting a patent application. 
•  Be prepared to listen to what the potential end users say. From 
the commercialization perspective, it does not really matter how 
significant the research is if the customer is not excited about 
the product. 
•  While the market research does not always indicate a need for 
the product that was first envisioned, a slightly different product 
might be of high interest. Having such knowledge can be worth 
a lot, so it is important not to become fixed with the first idea. 
4.2 Market potential
Determining the market potential and the market value of a patented 
or patentable biomarker involves taking into account e.g. the invention’s 
degree of readiness, the size of the market (as number of tests) and the 
competition situation. To ensure that the foreseeable profits exceed the 
high costs of patenting, the invention needs to have a significant market 
potential and target a growing market.
IVD tests for prevalent diseases will obviously have more extensive 
market potential than tests for rare diseases. From the perspective of busi-
ness, tests targeting large populations have higher market potential and are 
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likely to be appealing to larger companies. The number of potential licensees 
and the expected value of license agreements increases at the same pace with 
the prevalence of the disease / size of the population to be tested. Develop-
ment of diagnostics for rare diseases may not be attractive for the private 
sector, forming the main client for technology transfer. However, since some 
companies specialize in them, it may also be a place for good collaboration.
BEST PRACTICES
•  Establishing the target population is an essential part of assessing 
the market potential for a biomarker assay. Who is tested and 
when? Everybody? Elderly? Adults? Kids? Newborn? Prenatal? 
Male? Female? Healthy? Sick? All sick or certain subpopulation? 
Before or after symptoms? Before or after diagnosis? 
•  Try to turn the target population into numbers and describe 
which share or percentage of the population could be reached 
by the new test nationally and internationally. (Also see chapter 
on prevalence.)
•  Description of the potential earning model (the business case) 
involves assessing how to make money with the invention. Who 
is the customer? What is the important need of the customer/
the market to which the invention brings solution to? What 
is the benefit for the customer? Perspectives of the clinician, 
the clinical laboratory, the healthcare funding organization are 
interconnected and of main importance. 
•  Analysis of the competitive edge includes answering questions 
such as who are the competitors and what are the alternative 
solutions? Will the invention replace or supplement the existing 
products? What is the main advantage of the new product? 
•  Completely new or complementary solutions that can just be 
added in the testing protocol will have more value than merely 
alternative solutions, especially if there is a well-established 
product on the market that needs to be displaced.
•  Once e.g. the above factors (naturally in addition to the clinical 
significance and benefit) are pre-established, actual market 
analyses can be ordered from several external actors. Contacting 
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the potential customers for feedback (on the non-confidential 
level) is an essential part of the task.
•  There are different pathways for regulatory approval of a new 
test that can also be considered in the economic evaluation. 
These include producing a diagnostic kit, laboratory-developed 
assay, analyte-specific reagents (mainly in the USA), or research-
use-only kit or reagents. The regulatory process is most stringent 
for diagnostic kits, but at the same time it ensures the widest use 
and highest return for a new test.
4.3 Competition analysis
4.3.1 Alternative biomarkers and assay formats  
To have commercial use, a novel IVD test not only needs to solve a true 
clinical problem and be backed-up by convincing evidence, but also 
somehow be better compared to the competing approaches or add value to 
the existing testing sequence.
Furthermore, the competition analysis must span the entire spectrum of 
different approaches. Many diseases have multiple biomarkers due to the 
involvement of different biochemical pathways, and many biomarkers can 
be measured at different molecular expression levels.
BEST PRACTICES
•  Describe the current routine testing practices (especially the 
golden standard) with their shortcomings.
•  Literature searches (both in scientific and patent databases) for 
alternative (competing) approaches to solve the above shortco-
mings should include analysing all the alternative scientific and 
commercial applications for the same indication, irrespective of 
the biomarkers or technical platforms employed. 
  ▫ The initial searches (to be added as references to the inven-
tion disclosure) are best performed by the research team 
who are the best experts on the advances and limitations of 
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their technology. 
  ▫ TTOs will then perform the more thorough literature 
searches that are useful for drafting a patent application 
and ensuring FTO.
•  It is important to recognize and describe the significant benefits 
of the new invention over the competing approaches. Accep-
table advantages include, e.g.
  ▫ Increased diagnostic sensitivity and specificity
  ▫ Earlier diagnoses (less advanced diseases with less compli-
cations)
  ▫ Earlier therapeutic actions (less costly treatment with better 
clinical outcomes)
  ▫ Improved convenience and patient compliance (e.g. less 
invasive sampling which is also likely to result in cost savings)
  ▫ Expected reduced number hospital admissions or length-
of-stay
  ▫ Cost savings in testing or other diagnostic procedures (by 
replacing or reducing more expensive testing and other 
procedures)
  ▫ Decreasing the number of invasive or harmful procedures.
•  If alternative applications do not exist, interviews of end users 
should be made and documented to ensure that the inven-
tion answers a topical and significant clinical question. Enco-
ding or hiding the exact solution allows communication on 
the non-confidential level (with care). An already filed patent 
application gives more freedom for the presentations, but also 
postpones the feedback. 
•  Following the competition on regular (or even irregular) basis 
is important, because new methods are constantly invented and 
singular surveys may give a false impression of non-existing 
competition. (Note that new patent applications become public 
only after 18-months.) 
•  Once a patent application is filed, the Office Actions (OAs) 
from patent authorities often contain valuable analysis of alter-
native solutions to the problem to be solved presented in the 
patent application. Re-visit the competition and FTO analyses 
to confirm that the advantages of the new method still exceeds 
those of the patent examiner’s findings.
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PITFALLS
•  Competing applications are sometimes not recognized even 
though they were for the exact same indication and had the same 
performance and practicability characteristics. This is mainly 
because they are executed on a different technical approach or 
using biomarkers belonging to a different molecular class.
•  Knowledge of competing methods also emerges during the 
patent prosecution process. Evaluation of competing methods 
should be made each time the patent authorities identify appli-
cations with same technical effect. Suggested time point for 
thorough evaluation is before entering the international Patent 
Cooperation Treaty (PCT) phase (evaluation then being based 
on the novelty and patentability report for the priority patent 
application) and national phase (evaluation then being based 
on the International Search Report (ISR) and Written Opinion 
(WOISA) or (at the latest) International Preliminary Report 
on Patentability (IPRP) of the PCT phase). The same decision 
making criteria is to be used before submitting the application, 
i.e. a clear and relevant competitive advantage must remain.
4.3.2 Self-competition
Sometimes the own improvements  made after own patent application 
compete with the markers and methods protected by the application. The 
new design is typically no longer patentable, when the inventive subject 
matter has become public after 18 months.
BEST PRACTICES
•  In research projects spanning multiple years, postponing of 
patenting in the early years is recommendable if there is a high 
likelihood that the invention will be further developed or supple-
mented later (unless you already can predict the future deve-
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4.4 Commercialization pathways and marketing
Commercialization refers to the utilization of an invention either by star-
ting a new company or by licensing or selling the invention and related IP 
to an existing enterprise. Providing paid services directly from the research 
unit is another alternative. The commercialization of an invention and IP 
is not a quick process and not all inventions sell. Commercialization of IP 
by sale or licensing is also referred to as technology transfer.
Although patenting may be the requirement for commercializa-
tion, patenting itself will not assure commercialization. The decision for 
commercial development is made by a company only after the clinical 
utility of a novel biomarker has been demonstrated. In addition, e.g. prac-
tical, technical, legal, financial and regulatory aspects will affect the decision.
BEST PRACTICES
•  Define the type and use of the biomarker: is it e.g. a screening 
or a companion diagnostic assay? The routes of commercializa-
tion and the importance of early company connections signifi-
cantly vary between different uses.
•  To the extent that is possible, compile analyses on market 
potential and landscape, competitors and potential partners, 
freedom-to-operate and most potential paths for commercia-
lization (start-ups, licensing, sales).
•  Inventors themselves are usually the best in describing the 
advantages of their inventions in detailed scientific discussions 
lopments, which is not often easy in case of new inventions). 
This allows ensuring that the most optimal embodiments are 
protected and offered for commercialization. However, postpo-
ning patenting also postpones publishing and one should have 
a strategy in place to optimize the schedule.
•  Involve a patent attorney in planning the patenting strategy.
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with potential partners. The commercializing discussions and 
agreement negotiations are handled by the TTO.
•  It has been noted globally that university inventions are most 
successfully commercialized to actors that the inventors are 
already familiar with, such as project partners and competitors 
(companies). Cooperation between the inventors and TTO’s 
will produce the best results in talking with the companies.
•  In addition to utilizing the contacts and collaboration partners, 
the active marketing efforts can comprise, e.g.
  ▫ Direct contacting of companies active in the field (with or 
without external commercialization consultants)
  ▫ Attending partnering events and exhibitions (with inven-
tion-specific brochures, posters, stands etc.)
  ▫ Virtual IPR exhibit show rooms (including TTO’s own 
web pages)
•  The TTO’s need to have a budget e.g. for the external market 
analyses (most preferably comprising contacting businesses for 
feedback on the planned product) and marketing efforts, IP 
valuation, and travelling to partnering events and conferences, 
where the invention portfolio can be presented. It will also give 
an opportunity to talking to end users and industry representa-





Most commercial partners will not consider licensing without respective intellectual property (IP) protection due to the competitive edge it 
provides. The existence of IP rights (IPR) is paramount, also in the eyes of 
investors. 
Furthermore, concrete IPR allows ensuring a share of profits to both to 
the inventors and the research organization after the launch of the product, 
typically as a certain percentage of income from the sales (royalty). Also see 
the chapters where the agreements and business models are discussed in 
more detail.
5.1 IPR issues in project lifecycle
5.1.1 Patents as a source of information 
It has been estimated that 70-85 % of information found in patent data-
bases cannot be found elsewhere. Those researchers that follow the paten-
ting field will have a significant advantage compared to those who are not 
up-to-date on the newest directions of commercial development.
Furthermore, the information contained in patent publications on 
new methods and products is much more detailed than can be found in 
scientific publications. From assay development perspective, patent publi-
cations can even contain direct product development tips since they often 
include solutions to special problems, which would otherwise only become 
apparent after long time of use and would be difficult to resolve without 
knowledge of the issue. One can also track down the main competitors in 
the field based on the patent publications.
BEST PRACTICES
•  Offer training for researchers on the use of free patent data-
bases (Espacenet by the European Patent Office and PATENT-
SCOPE by WIPO) on a regular basis.
•  Guide the researchers in performing own preliminary novelty 
and FTO searches and interpreting patent claims where needed.
•  Especially Chinese and Korean patent applications are in conti-
nuous increase. The machine translations are fairly good and 
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are accessible free-of-charge directly from the patent database 
websites.
•  The patent databases can be searched e.g. by keywords, inventor, 
applicants, and application numbers. Patent classification codes 
can be used in more advanced searches.
5.1.2 Novelty of research
Producing new information will obviously have the highest impact on 
society. Staying aware of what other academic (or commercial) groups are 
doing and taking prior art and state-of-the art into account already when 
planning a new project will help in ensuring high standard and pioneering 
research and avoiding investigating again something that is known already.
BEST PRACTICES
•  Carry out novelty searches utilizing both scientific and patent 
databases. Abstracts of relevant conferences also often give a 
small peek on the state-of-the-art. Searches made when plan-
ning a new project will help to ensure that one is not researching 
already known matter again. Searches should also be made 
during the research projects each time, when significant new 
and potentially inventive results are established. The previously 
published materials are referred to as ‘Prior Art’.
•  Patent applications give a view of the direction where the deve-
lopment is going. A long and expensive product development 
process may only be apparent by a company’s patent application.
•  Patent applications also give a view of the possible partners or 
competitors.
•  While the patent slang can at first feel like a foreign language 
because of the specific terminology and repetitive structure of 
the patent publication, one will get used to it.
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•  The purpose of the patent publication’s repetitive structure and 
wording is applying patent protection for an accurately and 
detailed defined invention in a structured and standardized 
format, and one will get used to the patent slang quickly.
•  A patent publication describes a solution to a technical problem, 
whereas a scientific publication is a more neutral research report. 
However, both describe an invention with sufficient detail so 
that a professional can understand and repeat it.
•  Patent claims, especially the independent patent claims (claim 
1 and others that do not refer to previous claims), will deter-
mine the patent’s scope of protection. The dependent claims 
represent the different embodiments of the invention. Patent 
claims are interpreted literally, with the help of the definitions 
given in the specification section.
•  Note that patent applications become public after only 18 
months from the filing date (priority date).
•  It is good practice to do a complementary novelty search before 
entering the PCT phase.
5.1.3 Patenting versus publishing: Alternative protection     
strategies for early phase inventions
In the university settings, publishing is an inherent part of the work. Scien-
tific publications and patenting are not mutually exclusive but the order 
matters. 
Most of the inventions that are declared in invention disclosures to the 
university are in a very early phase. Yet, there may be significant pressure to 
protecting before publishing. Innovation must, however, be appropriately 
balanced with proof to be amenable to patenting. In the above situation, 
the exemplary strategies for protection include:
1.  Not pursuing for patent protection (due to lack of sufficient 
amount of verification data and scientific evidence).
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2. Filing a provisional (or similar non-searched) patent applica-
tion using the manuscript to be published and subsequently 
filing a PCT patent application within one year on the condi-
tion that proof-of-concept data has been established).
3. Filing a conventional patent application based on the manus-
cript to be published.
The pros for the above situations are:
1. You have followed the criteria you have set for protection of 
biomarker inventions.
2. You will save in patenting costs in the case the verification 
studies or establishing the prototype fails. The official fees for 
provisional (i.e., non-searched) applications are low. Involving 
a patent attorney will increase the costs but also the quality of 
the application.
3. The new test might turn out to be a commercial success early 
on (although this rarely happens).
The cons for the above situations are:
1. The invention cannot be protected after it has been published. 
2. You will not have the official novelty and patentability reports 
to support the drafting of the PCT patent application and 
patent claims. You may end up in pursuing too wide or too 
narrow scope of protection without a proper chance to amend 
the application. This can result in high patent prosecution costs. 
3. There is a chance that the verification and proof-of-concept 
data either do not support the application or remain missing. 
Prepare to terminate the application process.
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Alternatives to tackle the above cons:
1. Move to the next case or see 2) and 3).
2. Use provisional applications only as an alternative to saying 
no, i.e. instead of strategy 1). Order a novelty and patenta-
bility survey or have the application searched at the patent 
office (you will need to submit patent claims with the manus-
cript). Proceed to filing a PCT application only in case the 
required (and convincing) data has been generated by the end 
of the priority year. As there has been a clear deadline (10-11 
months) for the further proof, it is a simple decision whether 
to proceed with patenting or not.
3. Communication of expectations combined with preparing 
to alternative scenarios is important. Collaborating with 
researchers, proceed to filing a PCT application only in case 
the agreed data has been generated by the end of the priority 
year. As there has been a clear deadline (10-11 months) for 
the further proof, it is a simple decision whether to continue 
patenting or not.
5.1.3.1 The “30-month” commercialization strategy by university TTOs
Patenting costs are significant and cumulate during the years. Especially 
the costs explode when the national phase is entered at 30 months (in some 
countries 31 months) from the priority date, i.e. the first filing date. At this 
point, the application exits the international PCT-phase where all commu-
nication is carried out with a single patent authority such as EPO (Euro-
pean Patent Office). However, patents are not granted in the PCT-phase. 
The granting (and the preceding further processing) is performed only by 
the national or regional patent authorities in the so-called “national phase”.
In the national phase, the same patent application is filed separately 
at each selected national or regional patent office. Many national offices 
require translating the application to their own official language and the 
translation costs come on top of the official filing fees. Furthermore, the 
yearly payments (which will run and increase for 20 years) start running 
already at the time of filing rather than at the time of grant. Even with a 
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limited country selection, the cumulative costs after entering the national 
phase easily pass 50 000 €. 
To restrict the investments in protecting and commercializing a single 
invention among the large number of inventions made yearly, the univer-
sity TTOs often put a time limit at the end of the PCT-phase, which may 
in some cases be irrespective of achievements made in the project, or some-
times reflect point 3) in the preceding chapter. Typically, if a partner for 
commercial utilization has not been found during the 30 months despite 
a reasonable amount of marketing and commercialization efforts, even the 
more promising applications may be terminated.
BEST PRACTICES
•  TTOs’ resources for patenting are limited and estimating the 
commercial potential for an invention beforehand is difficult. 
To allow fair chances to different technologies and teams, TTOs 
often set milestones that need to have passed for continuing 
patenting either to the international PCT-phase (at 12 months) 
or to the hugely expensive national phase (at 30 months). The 
first time limit (12 months) more often reflects the success of 
data generation (e.g. verification results combined with further 
convincing scientific evidence), while the latter time limit (30 
months) more reflects the existence of commercial interest by 
companies towards the invention.
•  The typical 30-month time limit means that it must (by this 
point) be clearly established that the invention has significant 
market potential, i.e. profits are expected to notably exceed any 
patenting and product development costs. Having entered into 
serious negotiations with companies planning to commercially 
utilize the invention is a sign (the sign) of such potential. The 
existence of sole interest towards the research (in the absence 
of willingness to negotiate for a licence) may be a polite way 
of saying “no” and may not encourage to continue investing 
in patent protection. However, a “no” from a company with a 
strong “yes” from the clinicians may be related to the strategic 
position of the company. Perform a survey on the market size and 
potential. Also see the chapter Establishing start-up companies. 
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•  Other reasons that may support the termination of paten-
ting and commercialization activities at 30-months (or other 
time) include lack of progress in taking the invention closer to 
commercialization (by establishing a specific prototype assay), 
negative opinion of the patenting authority (lack of novelty or 
inventiveness), or the scientists leaving for other organizations 
(active contribution of inventors is no longer available).
•  However, one rule does not fit all fields and this also applies 
to the 30-month rule. Especially in IVD assay development, 
the road from biomarker discovery to use in clinical routine is 
long. If the research organization wants to invest in the research 
of new biomarkers, other criteria for decision-making can be 
used instead of the patenting-derived deadlines or strict mone-
tary restrictions. Such alternative criteria include e.g. the success 
rate in achieving specific milestones or the level of progress as 
compared to a pre-set development plan. Enthusiastic teams 
with good progress rate and high compliance to a development 
plan could be picked for continued patent prosecution process 
and commercialization actions. 
5.1.4 Increasing the innovation activity
The majority of significant research results and inventions is published 
before their protection possibilities and commercial potential have been 
assessed and evaluated.
BEST PRACTICES
•  The suggestions for increasing the awareness and activity for 
commercial utilization of university-based inventions include 
e.g.:
  ▫ Educating researchers on IPR-related matters earlier in the 
project life cycle, already at the time of filing funding appli-
cations
  ▫ Internal marketing of the services and personnel the univer-
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sity has for making e.g. novelty, patentability and FTO 
surveys, reviewing and handling invention disclosures, and 
finding the best fitting commercialization paths and part-
ners for the university-based inventions
  ▫ Bringing up success cases in internal newsletters or internal 
web pages
  ▫ TTO pop-up tents and stands at the campus
  ▫ Lunch meetings (or any repeating contacts) with the most 
innovative scientists and teams to be kept updated on 
recent progresses 
  ▫ Invention and business idea contests
  ▫ Regular IPR training of researchers
  ▫ Classes on IPR issues incorporated in basic and graduate 
student’s training programs
  ▫ Assigning and properly training an innovation “scout” for 
each faculty to educate researchers in identifying and decla-
ring inventions.
5.1.4.1 Inventor’s participation in the patenting and commercialization 
activities
Active participation of the researcher-inventors is crucial for successful 
technology transfer – the inventors cannot just give over the research 
completely and have nothing to do with the subsequent protection and 
commercialization steps. The enthusiasm and cooperation by inventors 
may even be a criteria of selection for starting the patenting and commer-
cialization activities.
In the other extreme, the researchers might be heavily involved for years 
with the company developing a product based on the biomarker invention. 
While the subvention of commercial companies by taxpayers’ money (i.e. 
work performed at the public sector for free) is not allowable, continuing 
support for the optimization, troubleshooting and clinical evidence buil-
ding for the new biomarker assay can be arranged in the form of paid cont-
ract research when agreed with the research team.
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BEST PRACTICES
•  Although patenting and commercialization of an invention is 
to the major extent carried out by the organization’s TTO and 
the external professionals appointed by the TTO, the inventors 
are expected to collaborate and give expert help to a reasonable 
extent in order to assist in protecting and commercializing the 
invention. The compensation paid by the university in the diffe-
rent steps of patent protecting and commercialization (as well 
as the share of potential future license and sales net revenues) is 
to cover all such endeavours so that separate fees do not need 
to be paid. 
•  The compensations paid at the different phases as well as the 
principle of sharing of the net income received as license or sales 
revenues need to be clearly specified in the organizations’ guide-
line for inventions. The different phases of payments and the 
minimum sums to be paid may be in part dictated by national 
laws.
•  The inventors’ contribution to patenting comprises e.g. 
reviewing the documents, providing additional calculations or 
results (where needed), providing argumentation for the bene-
fits of the invention, and signing the declaration and assign-
ment documents required by the patent authorities and agents.
•  The inventors’ contribution to commercialization comprises 
e.g. participating in the scientific discussions with the industrial 
parties (e.g. by giving presentations and reporting results), 
running specimen panels provided by the companies, and active 
sharing of any new contact and potential partner information 
with the TTO.
•  The inventors need also to accept to maintain secrecy and not 
to give to any third party information concerning the invention 
while the patent protection and commercialization activities are 
ongoing. However, in the academia, publishing the results is 
typically allowed after a patent application has been filed. 
•  A large share of the licensees of the university-born inventions 
are current or former collaboration partners, emphasizing the 
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role of the inventors in finding the best fitting commercializa-
tion partners for their inventions. 
•  If the university decides not to continue the protection or 
commercialization of the invention, the inventors may be 
offered the possibility to reclaim the rejected invention with 
terms that can be negotiated separately.
5.1.5 Dealing with discrepancies 
There is high competition between scientists and research groups. Unfor-
tunately, not all the research lasts closer inspection. It is also possible that 
there are cultural or other differences in comprehending what kind of accu-
racy is expected. Sometimes, the research and the related materials move to 
a new organization with the principal investigator, and some institutions 
now require filling and signing a “customs check” type of form together 
with the employment contract.
BEST PRACTICES FOR THE TTOS
•  Do not be afraid of asking difficult questions if you see contra-
dictions or note that some pieces are missing, e.g. if the origin 
of key materials is unclear, the obtained results do not match 
with the methodology, data has been heavily manipulated or 
normalized, the statistics show distortions, or the conclusions 
seem unjustified.
•  Ask again if there seems to be a barrier of language or other 
misunderstanding of the question.
•  Make memorandums of meetings and phone calls and send 
them to all parties. They will have an opportunity to correct 
any misunderstandings and you will secure proper agreement 
between all parties. Also, summarize in writing any important 
piece of advice you give orally.
•  Use an external consult if you think there is something that 
needs to be checked.
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•  If you already went ahead with a case that turns out rotten, 
consult your team, your superior, the university’s legal depart-
ment and the management as appropriate, and proceed accor-
ding to the organizational and national guidelines (including 
those for research ethics). Close cases that compromise the 
university’s reputation.
•  You can neither check nor know everything. Trust is an essen-
tial part of the process. TTOs focus is in the business, not chec-
king the validity of research methods or results. The researchers 
are expected to assure (e.g. by signing an invention disclosure) 
that all data provided is real and no mimicked, extrapolated, 
expected or otherwise strongly manipulated data is provided in 
place of actual findings.
•  There are plenty of guidelines and acts on research ethics, 
responsible project leadership and conflict-of-interest issues, 
which are not within the scope of the current handbook. 
5.2 Prerequisites of patenting
5.2.1 Novelty
Novelty means that an invention is different from earlier solutions disclosed 
in prior art. An invention cannot be patented if it has already been published 
by anyone, anywhere at the date of filing the patent application. 
Publishing, and thereby forming an obstacle for novelty, refers to 
abstracts, posters, oral presentations (elsewhere than in internal closed 
meetings), articles, electronic and printed news, patent applications as well 
as brochures and marketing materials. It needs also be ensured that the data 
is not published accidentally (e.g. as presentation slides posted on a website 
after a closed meeting) or by an external party.
BEST PRACTICES
•  Performing a preliminary novelty search is important (also see 
chapters 5.1.1 and 5.2.2). A thorough novelty and patentability 
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survey can be ordered from an external service provider once 
there is sufficient confidence based on an internal search.
•  As the simplest first step, ask the researchers for their earlier 
publications (including abstracts, presentations etc.) as well 
as other closely related research by other groups. Search the 
researchers by name in the internet to find e.g. interviews or 
other public disclosures. 
PITFALLS
•  In academia, novelty is often destroyed by own publications 
that may come up only after a patent application is searched 
for novelty by the patent authorities. The publications (articles, 
abstracts, posters, public presentations) by the research team 
would need to be disclosed and reviewed more closely at the 
time of handling the invention disclosures. 
5.2.2 Inventiveness
Inventiveness means a non-obvious or even surprising (1 + 1 > 2) solution to 
a technical problem. An invention must not be evident for a person skilled 
in the art or be possible to achieve with basic optimization or routine trials.
In the most optimal case, a previously unknown biomarker with clinical 
relevance is found, making it simpler and more straightforward to argue for 
both novelty and inventiveness. As this is not often the case with biomarker 
inventions, Figure 1 describes some alternative examples of scientific 
findings that might be in some cases and with some boundary conditions 
be considered for patenting. However, as described in the previous chap-
ters, many other conditions than novelty and inventiveness must be met to 
make the decision of patenting. 
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PITFALLS
•  Abstracts submitted to conferences are not considered very 
dangerous by the researchers if they have censored or coded the 
details. However, from the perspective of inventiveness, such 
a publication proves that a similar technical effect has been 
accomplished earlier. A patent application describing the inven-
tion in full may then be considered only to provide alternative 
markers for achieving the same technical effect than described 
earlier without details. This so-called non-enabling prior art is 
known for not destroying novelty but destroying inventiveness.
Figure 1. Examples of scientific findings that could be considered for patenting. 
All the examples refer to a situation where the biomarker and its correlation to a 
condition are already known in the prior art. The Figure is provided through the 
courtesy of HØIBERG European Patent Attorneys (2019).
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Freedom-to-operate means not infringing the IPR rights (almost always 
patents) of others and not needing licenses -- that may be costly or 
unavailable -- for IP owned by third parties when commercializing the 
invention. For example, to use reagents (such as antibodies) in a commer-
cial kit, one needs to agree with the provider that the use of the component 
in a commercial product is allowed. The cost may be different. Further-
more, one needs to make a survey that there are no existing method patents 
that would cover the use of the reagent in the same indication.
BEST PRACTICES
•  Compare the invention (as a whole) against existing patents 
and patent applications preferably already before generating 
own IPR. Pay special attention to key components that you 
cannot replace (such as rare antibodies).
•  While FTO surveys can be purchased from several external 
actors, initial searches made by the inventors themselves 
increases their knowledge of the state-of-the-art and helps 
in not becoming dependent of IP owned by others in future 
projects. Purchased FTO surveys tend to be expensive (>10.000 
€) and come therefore too late, i.e. when the product design is 
relatively fixed already.
•  An initial FTO study should preferably be performed already 
after the early phase, before proceeding to assay development 
phase, so that obsolete or non-commercially-available (for 
further commercial use!) components or sequences are not used 
accidentally.
•  Gaps in FTO detected any time before patenting may help in 
addressing the issue in the laboratory and in the patent applica-
tion. In some cases alternative, free-to-use reagents and methods 
can be employed. If not, proceeding to pursue patent protection 
requires strong reasoning.
•  Hindrances for FTO detected during patent prosecution must 
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also be taken into account when making decisions on the conti-
nuance. Ask your patent attorneys to also report suspected FTO 
issues in their reports. Although not perceived as hindrances for 
patenting, they can be significant hindrances for commercia-
lization. 
•  The need for third-party licenses should be allowed only rarely 
and only for elementary patents in which case a license is needed 
by all competitors, too. 
•  Take into account the expiry date and territorial coverage of the 
FTO-restricting patents.
•  Note that some assays (such as nucleic acid assays) and 
chemistries (such as labelling reagents) can easily be executed 
with alternative technologies and chemistries although not 
familiar to the researchers. In such a case, the non-commer-
cial proof-of-concept experiments may be based on a protected 
assay principle or chemistry. The commercialization partner can 
then execute the assay using the techniques and chemistries they 
prefer.
PITFALLS
•  An invention with restricted FTO means that the potential 
licensee also needs to negotiate and pay for other licenses before 
being able to commercialize the invention.
•  For some fundamental technologies, commercial licenses may 
be readily available. The license fees for manufacturing and 
selling IVD assay kits are, however, significantly high compared 
to in-house or non-clinical assays such as animal or food safety 
testing.
•  FTO may be compromised from the get-go if existing Back-
ground material is further developed in a publicly funded project 
where the project agreement (or MTA) limits the commer-
cial use of so-forming Foreground materials/data. While an 
72
industry partner may suggest to retain all the rights to materials 
the company is supplying for the project, including the possible 
improvements made, the national laws typically prohibit subsi-
ding private property with public funds. This means that the 
research organizations cannot (even by agreement) automati-
cally transfer the industrial parties the right to commercially 
utilize the Foreground, but utilization can be separately nego-
tiated at a market value price. However, the industrial partners 
may be offered the right of first refusal, i.e., priority of entering 
into an agreement (at market price) before external compa-
nies have been notified or approached. Similarly to above, the 
commercial utilization of other reagents, materials or software 
used in a research project may turn out to be prohibited. All 
restrictions and the potential to later violate third party rights 
need to be identified and tackled before the project starts.
5.4 Scope of patent protection
The most important characteristic of a patent is its scope of protection, 
which defines whether it can be easily circumvented or not - in other words, 
whether potential utilizers need a license for it or not. 
Broad patent claims are especially important in the case of universi-
ty-based inventions for which the motivation for patenting lies in techno-
logy transfer, that is, selling or licensing the IPR for companies for a fee. This 
approach significantly differs from that of the industry, where the primary 
aim of patenting is typically not out-licensing but protecting the existing or 
upcoming products and/or increasing the value of the enterprise. 
From this perspective, some type of biomarker inventions are difficult 
to patent well. A weak patent is any patent that opens up the possibility for 
the potential utilizer to circumvent the patent claims by replacing the least 
meaningful limiting feature of the independent patent claim by another 
solution that works similarly well.
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•  Biomarker panels/patterns/signatures: The current evidence 
shows that many tests are likely to rely on multiple biomarkers 
in the future. It is, however, more complex to get regulatory 
approvals and solid patent protection for multiplex biomarker 
tests than the singular assays, as the more biomarkers that are 
required in the claim, the easier it will be for third parties to 
replace one or more of the biomarkers and thereby circumvent 
the patent 
•  Furthermore, the larger the number of markers in a combina-
tion, the easier it becomes to replace one marker with another 
(or several) outside the list. In the case, only a pre-defined set of 
biomarkers (“signature”) seems be patentable, preferably only 
the very top marker(s) absolutely needed for the method to work 
should be included in the independent patent claim(s). The 
remaining markers should be put in a priority order and listed 
in dependent claim(s). If the inventors only have an unpriori-
tized list of candidate biomarkers that work in several different 
combinations, unity of invention will certainly be an issue and 
it will be difficult to obtain strong patent protection. This is 
also to avoid a “lack of unity” objection, which is easily received 
from the patent examiners when claiming an unprioritized list 
of biomarkers that work in several different combinations.
•  Sequences: Nucleic acid and protein sequences typically have 
room for minor adjustments especially around the key binding 
units. It is difficult to protect complex nucleic acid or peptide 
sequences so that all solutions that work in an assay would be 
covered. In the case of new biomarker findings, it is impor-
tant to try to search options for protecting the new assay by 
the target, without strictly defining the actual binders. The 
exact sequences should only act as examples and be described 
in the dependent claims. This also applies to new antibodies 
against existing biomarkers. The commercial value of antibo-
dies easily replaceable by other antibodies (with slightly diffe-
rent sequences) is very low relative to patenting costs. Patenting 
of antibodies and nucleic acid assays is feasible only when the 
claims permit covering virtually any binders for the same. 
Things that are difficult to patent well:
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•  Methods for production of diagnostic assay: When use of a 
patented production method is not evident from the diagnostic 
assay itself or its public documentation, infringements are 
difficult to monitor. The burden of proof is always at the IPR 
owner. The new method might result in significant savings in 
the manufacture of a specific product, but if the same could also 
be reached by other means, one could never be sure if the poten-
tial but reluctant client was already using the method or not.
•  Patenting in the USA: Due to a number of Court decisions 
over recent years, it is currently not possible to patent natu-
rally occurring products in the US, such as naturally occurring 
nucleic acids, amino acid sequences and fragments thereof. It 
is defined by the patent authorities as “Law of Nature”. It is 
however possible to patent variants of such naturally occurring 
products/sequences.
•  In addition, it is also very difficult to patent diagnostic methods 
in the US unless the biomarker is measured by unconventional 
means and/or a post-solution activity is added to the claim, 
usually in the form of a treatment step with a specific drug 
(companion diagnostic claims).  
•  For all the above cases it needs to be noted that patent prote-
ction by research organizations is not pursued to ensure FTO 
of own products but the goal is in out-licensing. It is therefore 
very important that the patents cannot easily be circumvented 
because the customer is purchasing IPR, not the final product.
Most solid form of patent protection, virtually covering all the different 
uses of a biomarker, can be achieved for biomarkers that are completely 
new, i.e. completely unknown in the prior art. In the current “omics” 
era, such findings are becoming more rare and often concern e.g. spli-
cing variants forming previously unknown mRNA and protein sequences 
that cannot be deduced from the genetic code. In such a case, even all the 
binders later developed to detect the new marker can fall under the scope 
of the original patent, similarly to all related IVD products to virtually any 
disease indication. 
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However, the much more common type of invention describes a new 
correlation between a known biomarker (or a group of known biomarkers) 
and a condition (see Figure 2 left panel). In many cases, successfully prote-
cting such new correlation provides a relatively wide coverage of related 
IVD products.
However, in the case that the correlation is known from prior art (see 
Figure 2 right panel), the biomarker invention might relate to providing 
more accuracy for assessing the condition in question. In such a case, 
competition and FTO analyses become increasingly important. Hindrances 
for FTO (due IPR owned by others) must be taken into account when 
making decisions on patenting. Although not preventing patenting, lack of 
FTO is a significant hindrance for commercialization.
Figure 2. Patenting new correlations versus improvements to known correlations 
between a biomarker (or a group of biomarkers) and a condition of interest. 
The Figure was provided through the courtesy of HØIBERG European Patent 
Attorneys (2019).
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•  To ensure that the university-owned IPR becomes interesting 
to companies, it is not enough to have an invention patented 
– it needs to be patented well and with broad enough patent 
claims so that the scope of protection is proper for the techno-
logy. Companies will only pay for rights they really need. 
•  If the intention is to form a start-up, the viewpoint of protec-
ting the planned products can be emphasized somewhat more.
•  Also, make a plan for the relevant territorial coverage of the 
patent family.
5.5 Other forms of IP and commercialization 
without IPR
Patent is the most important form of IPR at research organizations and 
most of technology transfer is based on licensing the patents to companies. 
However, not all inventions can and needs to be protected with a patent. 
In some cases, a patent may be impossible to get (e.g. due to lack of 
novelty/inventiveness or non-technical nature of the invention) or the fore-
seeable scope of the patent may too narrow to justify the high costs of 
patenting. Furthermore, to obtain a patent means that the invention must 
be fully revealed in the patent application, including detailed descriptions 
of materials and methods required to set the assay up. The patent appli-
cation (unless withdrawn) will become public in 18 months and it is no 
longer possible to keep the invention as trade secret after that.
In case of IVD-applicable biomarker assays, patents remain to be the 
decisive form of IPR in technology transfer. In most cases, it would anyway 
be difficult to keep secrecy of the analytes measured. In the healthcare 
settings, clinicians would rarely rely on “black box” tests without a possibi-
lity to understand the results obtained. Furthermore, the submissions for 
regulatory approvals are in some respects public.
IVD assays are naturally also launched and sold without patent protec-
tion. Other forms of IPR such as registered trademarks may help a company 
to achieve a foothold on the market, but competition for the underlying 
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•  Knowledge transfer – e.g. instructions, recipes, results and 
other documents specified in a license agreement
•  Database licensing – e.g. access to clinical data, raw data and/
or results database
•  Copyright – e.g. computer software
•  Trade secrets – e.g. complex algorithms in connection with 
biomarker signatures
•  Material licensing – e.g. cell lines and antibodies. 
Providing services-for-fee directly from the unit is another means 
for commercializing special knowhow.
5.6 Termination of protection and commercialization 
activities
Many research organizations file a double-digit number of new patent 
applications yearly. The maintenance of a patent portfolio is a resource-in-
tensive, long and costly process. The rules and timing of termination when 
a partner for utilization has not been found with reasonable efforts need to 
be transparent and understandable.
BEST PRACTICES
•  At a TTO, establish basic rules when patenting and commer-
cializing activities are to be terminated, e.g.
  ▫ required evidence has not been established within the prio-
rity year, or it shows low clinical utility
technology is then free and it is not likely that any single company reaches 
a monopoly for an important marker. 
From the perspective of technology transfer, non-patent IP transfer stra-
tegies can include, for example:
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  ▫ patent protection with sufficient scope of protection is not 
possible
  ▫ active contribution of inventors is needed but it is no 
longer available
  ▫ the commercial potential of the invention proves to be 
lower than was expected (e.g. due to limitations in FTO or 
target population)
  ▫ a partner for utilization has not been identified by the time 
of national phase of patent prosecution (the 30-month 
strategy)
•  After the decision to terminate, the inventors can be offered the 








6.1 Material transfer agreements (MTAs)
6.1.1 MTA-in
While the ownership of a university-based invention (or other intellectual 
property or knowhow) is determined at each organization according to the 
national laws that take into account e.g. the type and terms of funding, it 
is important to also know about other engagements the researchers have 
made related to the invention.
Special attention needs to be paid, for example, to the use of third party 
materials under a material transfer agreement (MTA). MTAs are made by 
researchers constantly and sometimes without reading the terms before 
signing. It is not the rarest situation that a compulsory license is granted 
based on an existing MTA. This is especially problematic if other licensees 
are blocked or non-existent.
BEST PRACTICES
•  Educate researchers to consult the university legal department 
when drafting any documents with companies or when modi-
fying the organizations MTA templates.
•  Educate researchers in how to interpret terms and conditions 
and to understand the main principles (background and fore-
ground results, ownership of results).
•  Educate researchers to think ahead about potential inventions, 
knowhow and other IP that may arise.
•  Secure the ownership of results obtained using a material 
provided under MTA. The material cannot be used commer-
cially, but the obtained results should be (e.g. in a patent appli-
cation or marketing materials).
•  The principal investigators also need to educate their teams on 
the binding terms of the MTAs made. They also need to reserve 
time for reporting as agreed in the MTA.
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PITFALLS
•  Materials should not be obtained from companies under a strict 
MTA if the same material is also commercially available (with a 
reasonable price).
•  An MTA made with a company remains to be in force although 
the material becomes commercially available from another 
source without restrictions.
•  Researcher accepts company MTA instead of using the MTA of 
his own organization and without consulting the legal department.
•  In the worst-case scenario, an invention made using the mate-
rial belongs to its provider in full.
•  In some cases, even publishing may require the permission of 
the provider. If the confidentially obligations are not followed 
and results are published, the organization may end up in court 
for a breach of agreement.
6.1.2 MTA-out
The new EU General Data Protection Regulation (GDPR; 2016/679; 
enforcement date 25.5.2018), is designed to harmonize data privacy laws 
across Europe, protect all EU citizens’ data privacy and give form to the 
way research organizations and industry approach data privacy. It sets more 
stringent requirements for the processes related to transferring clinical 
specimen materials and needs to be taken into account in related MTAs.
BEST PRACTICES
•  The new EU-regulations need to be taken into account in all 
MTAs that relate to patient specimen materials so that the follo-
wing processes are described:
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1. De-identification of the information of donors so that tracing 
back by the Receiver becomes impossible
2. Informing the receiver of any restrictions relating to the use (or 
further transfer) of the materials
3. Maintaining the chain-of-custody of the materials 
4. Ensuring there are no restrictions of using the material for the 
purpose intended. The patient consent must allow using speci-
mens for the purpose (in a wider sense) and the Provider must 
have the right to transfer the material.
5. Ensuring that unused materials are properly disposed of in 
accordance with applicable laws and related ethical approvals.
6.2 Non-disclosure agreements (NDAs)
A Non-Disclosure Agreement (NDA) is an agreement of keeping confi-
dential information secret according to terms and duration described in 
the agreement. It is the same as CDA (Confidential Disclosure Agreement).
BEST PRACTICES
•  An unprotected invention or other unprotected intellectual 
property or knowhow should only be presented to business 
partners after making a NDA. An NDA will be needed if the 
upcoming negotiations or discussions will contain information 
that is not published or publicly available, not already known 
(by the company) and is not IP protected.
•  For initial discussions and feedback, however, the invention or 
knowhow can often be coded so that first presentations can be 
given on the non-confidential level (the same with the potential 
end users). For example, you can tell that you found protein 
or genomic markers A and B that, when existing in a clinical 
specimen together, will indicate with 90  % diagnostic accu-
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racy (or any of the real calculations you have) that the disease is 
aggressive and the patient will benefit from surgery. Make yet 
a notification that the material is for internal use only and not 
meant to be distributed.
•  NDA’s are is force typically 2-5 years (or less if the invention is 
published).
6.3 Business models
6.3.1 Licensing versus sales of IPR
When selecting between feasible agreement models, at least the following 
variables are to be reviewed: 
•  Degree of readiness: the amount of product development 
contributions needed; possibilities for refining the invention 
in-house (e.g. further proof-of-concept studies)
•  Size and growth rate of the market: what is the share that could 
be obtained
•  Competition analysis: what are the alternative solutions, how 
significant the invention is
•  Scope of patent: coverage (extent) of the patent claims, possibi-
lities for circumventing
•  Circumstances in which the invention was made and the terms 
of funding (contract research)
•  Number of companies interested (or parties in contract research) 
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Licensing of IPR may be more advantageous when: 
•  The research continues and the invention can be used as back-
ground material (must be taken into account in the terms*)
•  Multiple licensing agreements are expected (e.g. via different 
territories or fields of use), increasing the potential cash flow
Sales of IPR may be more advantageous when: 
•  When unreasonably large patenting costs are expected compared 
to the foreseeable income
•  When the number of potential licensees is very limited 
•  When it facilitates establishing a new business activity or 
start-up by the research team.
* When there are prospects for further research, the primary commercia-
lization path is non-exclusive licensing wherein the university retains the 
right of ownership and further utilisation rights. However, whether this is 
possible depends on the possible project agreement, the invention and the 
utilization parties. When the rights to an invention have been sold exclusi-
vely, the invention can no longer act as background material when applying 
for public research funding.
6.3.2 Negotiations with alternative term sheets
The companies often wish for more transparent negotiations for the univer-
sity-IPR licenses and the availability of alternative agreement models from 




•  In situations where several alternative agreement models are 
feasible, provide the potential licensee with the selected models 
for review e.g. in the form of a term sheet. Include at least the 
following specifics and variables:
  ▫ Licensor, licensee, date
  ▫ Technology: name or description
  ▫ The exact IPR: invention disclosures, patent/patent appli-
cation(s), trademarks, knowhow, materials etc.
  ▫ Territory
  ▫ Field of use
  ▫ Type of agreement: sales or licensing (exclusive, sole or 
non-exclusive), or if these are alternative models
  ▫ The different balances between up-front payments, royal-
ties and/or annual fees
  ▫ Ownership of rights (transferred or remain with the 
licensor)
  ▫ Patenting costs (who pays, in what extent and when)
  ▫ Decision maker in patent procurement issues
  ▫ Sublicensing issues (right to grant; payments/royalties)
  ▫ Infringements
  ▫ (Duration, diligence requirements, milestone fees etc. case-
by-case)
•  Also define the target and scope of the agreement properly, 
i.e. whether it comprises a method (e.g. invention disclosure 
or patent application for a biomarker assay) and/or materials 
(e.g. clone for producing a specific antibody). Also describe 
any possible specimen materials transferred (also see chapter on 
MTA-out).
6.3.3 Establishing start-up companies 
If the invention is significant and targets a growing market, the researchers 
might themselves be motivated to form an entrepreneur team. However, 
the circumstances, ownership of inventions and opportunities for funding 
87
differ between countries and are to be taken into account. Where feasible, 
having ownership of the respective IPR may play an important role in crea-
ting value for a new start-up company and in the acquisition of funding for 
the first rounds.
BEST PRACTICES
•  Establishing a new company can be justified if:
  ▫ The researchers have or can acquire ownership (or licence) 
to the IPR
  ▫ There is an important market need that the invention 
brings a solution to
  ▫ The protection of the invention is proving successful
  ▫ The expected product development contributions are 
reasonable / in-scale with comparable approaches
  ▫ The founders have endurance to undertake all the labour-in-
tensive tasks of e.g. product development, quality assu-
rance, transfer-to-production, registration & approvals, 
marketing, production, sales and distribution, understan-
ding that at the maximum of 10 % of the work is done at 
the end of a research project (with a prototype or proof-of-
concept assay).
  ▫ The business plan is sound enough to make external 
funding realistically possible
  ▫ The business potential is sufficient to provide not only a 
decent livelihood for researchers, who are becoming full-
time or part-time entrepreneurs, but also a growing cash 
flow that will later cover new product development – very 
few enterprises are successful with one product only
  ▫ Conflict-of-interest issues are taken into account, i.e. the 
business does not compete with the main employee (in case 
of part-time entrepreneurs)
  ▫ A business-oriented CEO has been identified
•  While the law prohibits subsiding private property with public 
funds (in other words meaning that the universities cannot offer 
corporations any services, materials or IPR below the market 
value), the universities are in many case open for negotiation to 
share the market risk in the early years of operation of a start-up. 
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When feasible (e.g., no other industrial parties have the priority 
to negotiate for commercial utilization), the universities with 
entrepreneurial mind-set may courage the new enterprises by 
offering them the ownership of the IP rights with flexible terms, 
including alternatives for directing the remuneration from 
down payments towards royalties. (Also see chapter on Agree-
ments and Terms.)
•  Universities may in some cases also participate as stakeholders 
in a new company and IPR can be transferred as an investment-
in-kind contribution.
PITFALLS
•  Sold IPR is the property of the new owner. Assigning IPR to 
a start-up typically means that the rights cannot be returned 
to the university in case the commercialization fails or the 
company goes bankrupt (as a contrary to licensed IPR). On the 
other hand, liability issues and patenting costs are transferred to 
the new owner as well. However, you can try to make a clause 
in the agreement on returning IPR to the university in case the 
company fails, but the typical risk is that the IPR will anyway be 
counted as property of the estate and sold to cover the losses of 
the creditors (unless you set a clause that allows predicting the 
bankruptcy well in time, e.g. lack of sufficient turnover). Other 
problems sometimes encountered relate to significant changes 
in the scope of the patent made during the patent prosecu-
tion process (to better cover the products of the company, but 
making the patent less useful for others). Also, having already 
seen the commercialization endeavours fail, the university may 
not be enthusiastic to have the possible termination discussions 
with the original inventors that may not have been involved 
with the IPR ever since, or who may not work at the university 
any longer. In other words, it all depends in the case and the 
value/adaptability of the invention. 
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•  When the payments are directed strongly from front payments 
to royalties (paid from the sales of products), the market risk 
may remain at the IPR seller for a long period of time. Public 
funding is tax-payers’ money and the university cannot there-
fore carry the entire risk of entrepreneurship without applying 
e.g. time limits, diligence requirements and/or yearly payments. 
•  Accepting equity as a replacement for a cash is a somewhat 
controversial issue and is not allowed by the IPR policy of the 
research organization. National differences may also exist. The 
pros include getting a share of any success of the company (also 
from other products than the licensed one) and that equity 
usually only replaces the down payment, not royalty. The cons 
concern the strong dilution of ownership after several rounds of 
investments, the non-liquidity of the possession, and labour-in-
tensiveness related to participation in board and general 
meetings, agreements etc.
6.3.3.1 Connections with investors
An investor is a person/group of people/company who invests in a start-up 
company, which usually carries an economic benefit. Since investors appear 
in different ways and pursue different investment strategies, they are often 
divided into different groups. Founders with a need for venture capital 
are often faced with the question of what kind of investors they should 
approach. The choice is usually between a private investor, a business angel 
or a venture capital company, but also other options exists). All provide 
capital, but differ in many other ways.
Private investors are a good option for capital seekers who do not want to 
grant a say in company decisions. They either participate as silent partners 
or provide the company with an interest-bearing loan. This group of inves-
tors is a good choice for start-ups that are still in their early stages as their 
focus is on the return potential and they can be promised a disproportio-
nate multiplication of the investment in the first few years. The investment 
volume of a private investor depends on its financial possibilities. In general, 
private investors could invest anything from a thousand euros up to several 
hundred thousand euros.
90
Business Angels are successful businessmen (or women) or former entre-
preneurs. They not only provide venture capital, but also usually want to 
actively participate in the company. There are now numerous business angel 
networks and pitching events for start-ups. As a rule, business angels parti-
cipate in very early business phases, sometimes even in the start-up phase, 
in order to contribute their knowledge and experience (industry know-how, 
large network, important contacts) as early as possible. This enables inexpe-
rienced founders in particular to avoid critical mistakes. Business angels are 
rather short- to medium-term oriented investors and participate in those 
phases where the investment risk is still highest and risk capital is very diffi-
cult to access for capital seekers. Their goals are to successfully position the 
company in the market and increase its value, and then to sell their shares 
profitably to a strategic investor or venture capital company after appro-
ximately two to five years. In contrast to private investors, business angels 
demand higher company shares. Depending on the level of investment, 
which averages between 50 000 and several hundred thousand euros , as 
well as the business model and company status, capital seekers should be 
prepared to sell 5 to 35 % of their company shares (usually with granting a 
say in company decisions). Founders and business angels should therefore 
be on the same wavelength and share similar views.
Venture capital companies are among the first port of call for many 
capital seekers. But especially for early-stage start-ups that do not yet have 
a proof-of-concept, they may not be the right kind of investors. Venture 
capital (VC) companies place high investment demands on capital seekers. 
Seeking to generate high profits, they want to avoid risks as far as possible. 
Capital seekers who can already demonstrate initial success and have a 
demonstrably functioning and scalable business model are suitable for 
approaching venture capital companies. The investment level of venture 
capital companies starts usually at least 250  000 euros, depending on 
the company, but can also be several million euros. Before the initial 
approach, start-ups should inform themselves about the industry focus and 
investment criteria of the venture capital companies in order not to address 
the wrong investors. In contrast to private investors or business angels, no 
individual decides on a capital commitment, but the decision is made by 
an investment committee. If founders attach great importance to their 
entrepreneurial freedom, they are not necessarily in good hands with a VC 
company. These usually have a far-reaching effect on the decision-making 
processes of start-ups. VC companies are a good choice for founders who 
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can get involved and want a financially strong and professional partner 
with a large network at their side. Start-ups planning to finance through a 
VC company should start the VC acquisition in good time and bring a lot 
of patience with them, because it can take up to twelve months until the 
final contract is signed and payment is received. 
BEST PRACTICES
•  When planning to establish a start-up and to search external 
funding from investors, have the first contact with early stage 
investors as early as possible, i.e. right after the IPR and owner-
ship questions have been discussed with the university. No 
agreements need yet to be finalized, but there should be an 
understanding of the alternative models of IPR transfer together 
with prices (e.g. in the form of a term sheet). 
•  Present the investors the medical need and the development 
plan. As investors undertake multiple project valuations at a 
time, the development plan has to be clear.
•  The team seeking for funding needs to have good knowledge of 
the limitations and competition in the field. In the case of new 
IVD assays, the current gold standards used in hospitals need to 
be presented and compared to.
•  Project valuation can and should be performed with several 
different investors to get a reliable assessment of the required 
investment. 
•  If available, prefer an investor who is familiar with the field and 
able to develop the technology further.
•  Especially the following aspects are relevant for an investor for 
decision-making: 
  ▫ Strong and credible team
  ▫ Innovative technology or business model from a high-tech 
industry
  ▫ Market prospects (need to be above average) 
  ▫ Risks foreseeable in the realization phase
  ▫ IPR, other guarantees
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  ▫ Existence and location of the company
  ▫ Rights for participation in and control of the company (not 
on the scientific R&D level as the team has competence 
there)
  ▫ Fit in the existing portfolio (diversification or synergy 
effects; networking)
•  The investors’ favourite patenting countries in the field include 





T he high discovery rate and low commercialization rate of university  born biomarker inventions highlight the need for selecting the best practices, 
or at least avoiding the pitfalls, when dealing with reviewing, protection and 
commercialization of IVD-applicable biomarker inventions.
The current collection of best practices and pitfalls aims in its part 
to help in ensuring that the research, patent protection and technology 
transfer processes at universities and research organizations are managed 
in a manner that supports their commercialization, taking seriously into 
account the needs and requirements of the companies and end users.
The common goal of all the stakeholders, after all, is to give rise to 
technically and economically practical, clinically informative IVD assays 
that can be commercialized with reasonable efforts and which ultimately 




The purpose of the Glossary is to define the terms that might have different 
meanings and to clarify how we use them in BiC. Any other definitions are 
used as they are presented in the IVDR glossary.
Analyte is a chemical substance that is the subject of (bio)chemical analysis 
(1); used in the definition of biomarker (1).
Biomarker is a molecular characteristic that can be objectively measured 
and evaluated as an indicator of a physiological or pathological process in 
an individual or an individual’s response to a therapeutic intervention. The 
closest synonym to a clinically useful biomarker in the context of in vitro 
diagnostics (IVD) is an analyte, i.e., a component (molecule) in a clinical 
sample the presence, absence or concentration of which is measured in 
an analytical procedure such as by a laboratory test to obtain information 
on an individual’s health status. The biomarker (or analyte) can e.g. be a 
nucleic acid, protein, polysaccharide or metabolite (2, 3, 4). Alterations 
found e.g. by clinical inspection, physical measurement of organ functions 
(e.g. blood pressure, cardiogram), or microscopy of visual tissue appearance 
i.e. digital biomarkers are not included in the scope of the current hand-
book. The scope is also narrowed down to human applications although 
many characteristics and requirements are similar for veterinary applica-
tions.
Biomarker commercialization (BiC) is the name of the current EU-pro-
ject which formed by 9 partners from the Baltic Sea Region (BSR). The 
main object of BiC is the development of new practical tools to support the 
different phases of IVD-applicable biomarker development and commer-
cialization process (5), assessing the maturity level of the biomarker inven-
tions and emphasizing the industry expectations. The ultimate goal is that 
the new tools will improve the understanding and collaboration between 
academia and industry and lead increased development of new and effec-
tive IVD diagnostics.
Biomarker signature is “the smallest set(s) of molecular quantities that are 
able to predict a given outcome (target) with maximal predictive perfor-
mance” (6). Synonym: panel of biomarkers. Examples include transcrip-
tomic, proteomic or metabolomic profiles of a disease. The concept was 
introduced by the advent of the new spectroscopic technologies such as 
liquid-chromatography mass-spectrometry or nuclear magnetic resonance 
spectroscopy. FDA introduces the term of composite biomarker consisting 
of “several individual biomarkers that are combined in a stated algorithm 
to reach a single interpretive readout” (7).
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Clinical significance refers to the practical importance of a scientific 
observation (8). It is used as a tool to quantitatively assess whether the 
magnitude of an observed difference is such that it is relevant to patients. 
Measures include e.g. effect size and risk ratios. In comparison, statistical 
significance refers to the likelihood of a difference being observed due to 
chance. It does not give information on the scale or direction of the diffe-
rence.
Feasibility study is an analysis and evaluation of a proposed project to 
determine if it (1) is technically feasible, (2) is feasible within the estimated 
cost, and (3) will be profitable. Feasibility studies are typically conducted 
before companies decide to invest in new product development (9). 
GxP is a general abbreviation for the "good practice" quality guidelines 
and regulations. The "x" stands for the various fields of ”good practice” (e. 
g. Good Manufacturing Practice, GMP; Good Laborabory Practice, GLP; 
Good Clinical Practice, GCP).
Health Technology Assessment (HTA) is a comprehensive, systematic 
assessment of the background for and the consequences of applying health 
technology. The purpose of HTA is to improve the basis for decisions about 
prioritisation and planning in the health area. HTA evaluates treatment 
methods to disseminate knowledge on the best use of health technologies. 
HTA contributes to quality development and efficient resource utilisation 
in any national health service (10). 
In vitro diagnostics (IVD) refers to tests (assays) used for in vitro examina-
tion of clinical specimens derived from the human body to provide infor-
mation on the health status of the subject. IVDs are essential tool in the 
everyday medical practice and most treatment decisions are based on the 
IVD results.  
In vitro diagnostic medical device regulation (IVDR) is the EU REGU-
LATION 2017/746 OF THE EUROPEAN PARLIAMENT AND OF 
THE COUNCIL of 5 April 2017 on in vitro diagnostic medical devices 
(11).  
Patent Cooperation Treaty (PCT) phase is the international patent prose-
cution phase managed by the World Intellectual Property Organization 
(WIPO). The PCT system facilitates the launch of the patent application 
in all the PCT member countries (now 152). Typically this phase starts at 
the end of the priority year (i.e. first year after filing the first national or 
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areal patent application for the same invention). At the end of the PCT 
process, the patent authority provides an International Preliminary Report 
on Patentability (IPRP). Patents are not, however, granted during the PCT 
phase but the prosecution process is continued in national and areal patent 
offices.
Payer means an entity (other than the patient) that finances or reimburses 
the cost of health services, such as public healthcare authority, insurance 
company, employer or union.
Product is generally “something that is made to be sold, usually something 
that is produced by an industrial process or something that is cultivated” 
(12). In the BIC project the term refers to a physical IVD test (i.e. assay) 
kit for measuring biomarker(s) (i.e. analyte(s)) in selected clinical settings 
(including home and near patient testing).
Proof of concept (PoC) is an “experimental work intended to verify that 
the concept works as expected in clinical setting or in real-life setting.” (13). 
POC studies are performed using a practical and targeted (specific) testing 
platform that could be commercialized and used with reasonable efforts.
Proof of principle (PoP) relates to the early biomarker development 
studies performed before the proof of concept phase. The methodology 
employed at this stage may be qualitative or semi-quantitative in nature 
and use instrumentation mainly available at research settings only. The 
clinical samples used in these early studies are typically heavily selected 
(e.g. paired samples of healthy and sick). 
Stakeholders in BiC include e.g. research organizations, health care provi-
ders (e. g. hospitals and clinical laboratories), clinicians, patients, IVD 
industry, investors, and health insurance companies.
Technology Readiness Level (TRL) analysis is the assessment of the matu-
rity of a discovery established by European regulations; it is based on an 
established scale, referring to whether it is a basic research, applied research, 
proof-of-concept, performance evaluation of prototype, integration/imple-
mentation, commercial design, or fully commercial deployment (13, 14, 
15, 16).
User, also End User or Intended User, means any healthcare or medical 
industry professional or lay person supposed to use the in vitro diagnostic 
medical device. 
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Before biomarker discoveries can be commercially utilized in clinical laboratories, many studies and surveys need to be completed and many questions answered. Is there a market need? Is there enough scientific 
and clinical evidence to convince the end users? Is the biomarker patentable? 
Is the translation into a practical product feasible?  
Although commercial product development is not the focus of academic 
research, the route to reach the patients will almost always require a professional 
commercialization process. Understanding industry and end-user requirements 
is essential for the successful commercialization of new biomarker assays.
The current handbook collects some of the best practices and pitfalls encoun-
tered at different phases of biomarker discovery, development, patent protec-
tion and technology transfer at universities, hospitals and research organiza-
tions. The focus is on in vitro diagnostics (IVD)-applicable biomarkers, i.e. 
markers intended to provide information on the health status of a person.
The input for the collection has been sought from true-life practices: 
•  practices found in literature or taught by experts in the field; 
•  opinions and expertise of different stakeholders (end users, companies, 
technology transfer professionals, researchers, financiers); 
•  recommendations, regulation and laws; 
•  as well as practices learned the hard way, i.e. repeatedly failing some-
where in the process and later adapting the process for increased success.
The main target group of the handbook comprises professionals working 
in Technology Transfer Offices (TTOs). The presented practices are yet not 
intended to be interpreted as strict rules but rather as a source of inspiration. 
Optimal ways to proceed with patenting and commercialization significantly 
vary between cases and circumstances.
